

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
21 December 2000 (21.12.2000)

PCT

(10) International Publication Number
WO 00/77204 A1(51) International Patent Classification⁷: C12N 15/12, 15/63, 5/10, C12Q 1/68, C07K 14/705, G01N 33/68, A01K 67/027.

(72) Inventors; and

(75) Inventors/Applicants (for US only): SCHWARTZ, David, A. [US/US]; 4810 Rapid Creek Road N.E., Iowa City, IA 52240 (US). SCHUTTE, Brian, C. [US/US]; 3378 Lower West Branch Road, Iowa City, IA 52245 (US).

(21) International Application Number: PCT/US00/15723

(74) Agent: VIKSNINS, Ann, S.; Schwegman, Lundberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402 (US).

(22) International Filing Date: 8 June 2000 (08.06.2000)

(25) Filing Language: English

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(30) Priority Data:
09/329,515 10 June 1999 (10.06.1999) US

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 09/329,515 (CIP)
Filed on 10 June 1999 (10.06.1999)**Published:**

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for all designated States except US): UNIVERSITY OF IOWA RESEARCH FOUNDATION [US/US]; 100 Oakdale Campus #214 TIC, Iowa City, IA 52242-5000 (US).

(71) Applicant and

(72) Inventor: LORENZ, Eva [US/US]; 33 Willowbridge Drive, Durham, NC 27707 (US).

(54) Title: VARIANT TLR4 NUCLEIC ACID AND USES THEREOF

A1

WO 00/77204

Human (aa 290)	. . .	L	A	Y	I	D	Y	Y	L	D	D	I	I	D	L	F	N	C	L	T	N	V	. . .
Mouse (aa 289)	. . .	L	T	Y	T	N	D	F	S	D	D	I	V	K	-	F	H	C	L	A	N	V	. . .
Rat (aa 289)	. . .	L	T	Y	I	N	H	F	S	D	D	I	Y	N	-	L	N	C	L	A	N	I	. . .
Hamster (aa 289)	. . .	F	T	Y	A	N	E	F	S	E	D	I	T	D	-	F	D	C	L	A	N	V	. . .



(57) Abstract: The invention provides methods to identify polymorphisms at the human TLR4 locus, as well as methods to identify individuals at risk of indications that increase their morbidity and mortality.

VARIANT TLR4 NUCLEIC ACID AND USES THEREOF

5

Statement of Government Rights

This invention was made at least in part with a grant from the Government of the United States of America (grants ES06537, ES07498 and ES05605 from the National Institute of Environmental Sciences, grant HL62628 from the National Heart and Lung Institute, and grant RR00059 from the 10 General Clinical Research Centers Program). The Government may have certain rights in the invention.

Background of the Invention

Endotoxin or lipopolysaccharide (LPS), released from the cell wall of 15 bacteria, plays a central role in a broad spectrum of human disease. The pathogenic importance of LPS in gram-negative sepsis is well established. Intravenous LPS induces all of the clinical features of gram-negative sepsis, including fever, shock, leukopenia followed by leukocytosis, and disseminated intravascular coagulation (Favorite et al., 1942). Higher concentrations of 20 circulating levels of endotoxin have been associated with manifestations of systemic inflammatory response syndrome (Wang et al., 1995) and the development of acute respiratory distress syndrome following sepsis (Brigham et al., 1986). Inhaled endotoxin can induce airflow obstruction in naive or previously unexposed subjects (Michel et al., 1992) and is the most important 25 occupational exposure associated with the development Schwartz et al., 1995a), and progression (Schwartz et al., 1995b), of airway disease among exposed workers. The concentration of endotoxin in the domestic setting appears to be associated with the clinical severity of asthma (Michel et al., 1996). Moreover, recent studies have shown that endotoxin is a contaminant of particulate matter 30 in air pollution and may play a role in the pathophysiologic consequences of air pollution (Bonner et al., 1998). Thus, endotoxin is an important cause of morbidity and mortality.

The ability of the host to respond to endotoxin may play an important role in determining the severity of the physiologic and biologic response to this 35 frequently encountered toxin. In mice, genetic differences in susceptibility to

frequently encountered toxin. In mice, genetic differences in susceptibility to LPS have been established. LPS hyporesponsiveness arose spontaneously and was first identified in the C3H/HeJ strain. This strain had an LD₅₀ for LPS at least 20 times that observed in A/HeJ mice (Sultzter et al., 1968). In addition to 5 C3H/HeJ, two other mouse strains, C57BL/10ScCR (Coutinho et al., 1978) and its progenitor strain, C57BL/10ScN, (Vogel et al., 1979), are hyporesponsive to LPS.

Moreover, several reports suggest that humans may also respond differently to LPS. A patient with recurrent bacterial infections has been 10 reported to be refractory to the *in vivo* and *in vitro* effects of LPS (Kuhns et al., 1997). Following challenge with intravenous LPS, this patient had no systemic increase in IL-6 or G-CSF and had a minimal rise in the concentration of leukocytes, TNF- α , and IL-8. Inter-individual differences have also been reported in the release and synthesis of cytokines by monocytes stimulated with 15 LPS *in vitro* (Santamaria et al., 1989).

LPS is thought to cause much of its morbidity and mortality by activating kinases (DeFranco et al., 1998) that control the function of transcription factors (nuclear factor- κ B and AP-1) and ultimately lead to production of pro-inflammatory cytokines and co-stimulatory molecules (Wright, 1999). Several 20 lines of evidence suggest that the toll receptor (TLR) family, and specifically TLR4 and TLR2 regulate the interaction between LPS and intracellular kinases and may serve as a proximal target to interrupt LPS signaling (Wright, 1998; Medzhitov et al., 1997). Both TLR4 and TLR2 activate signaling through NF- κ B and AP-1 in transfected human cell lines (Medzhitov et al., 1997; Yang et al., 25 1998), and TLR4 mediates LPS induced signal transduction (Chow et al., 1999). CD14, a glycosylphosphatidyl inositol-linked receptor that binds LPS (Poltorak et al., 1998a) enhances LPS-induced TLR2 (Yanget al., 1998) and TLR4 (Chow et al., 1998) signaling, suggesting that the toll receptors interact with CD14 to initiate the cellular response to LPS. Studies in mice indicate that 1) the TLR4 30 gene maps to the critical region in LPS hyporesponsive mice (Poltorak et al., 1998), 2) mutations in the TLR4 gene (Poltorak et al., 1998; Qureshi et al., 1999) are found in mouse strains (C3H/HeJ and C57BL10/ScCr) that are defective in

their response to LPS, and 3) disruption of the TLR4 gene results in a LPS hyporesponsive phenotype (Hoshino et al., 1999).

Thus, there is need to determine whether the human TLR4 gene is polymorphic, and whether any particular polymorphism is associated with disease, e.g., LPS hyporesponsiveness.

Summary of the Invention

The invention provides a method to identify a mammal, e.g., a human, at risk of, or having, an indication associated with altered innate immunity, e.g., to bacterial infection. The method comprises contacting an amount of DNA obtained from a human physiological sample with an amount of at least one TLR4-specific oligonucleotide under conditions effective to amplify the DNA so as to yield amplified DNA. Then it is determined whether the amplified DNA comprises a nucleotide substitution, e.g., one that results in an amino acid substitution, i.e., the TLR4 DNA of the human encodes a variant TLR4. Thus, the invention is useful to detect polymorphisms in the TLR4 gene.

Normal healthy, non-asthmatic subjects demonstrate a reproducible airway response to an incremental LPS inhalation challenge test, with some subjects developing airflow obstruction when challenged with low concentrations of LPS and others virtually unaffected by high concentrations of inhaled LPS. These findings suggest that the spectrum of LPS responsiveness in humans is quite variable from one individual to the next (but reproducible within an individual), and that a substantial portion of the population may be hyporesponsive to inhaled LPS. As described hereinbelow, an incremental LPS inhalation challenge test was employed to reliably phenotype individuals as either responsive (at least a 20 % decline in the forced expiratory volume in one second (FEV₁) after inhaling up to 41.5 µg LPS) or hyporesponsive (FEV₁ > 80 % of their baseline after inhaling 41.5 µg of LPS) to inhaled LPS. Fifty-two (63 %) of these individuals were responsive to inhaled LPS and 31 (37 %) were hyporesponsive to inhaled LPS.

These results were employed to determine the relationship between polymorphisms in the TLR4 gene and the airway response to inhaled LPS in the 83 normal healthy, non-asthmatic subjects. Using single stranded

conformational variant (SSCV) analysis and direct sequencing, a missense mutation (A896G) was identified in the fourth exon of the TLR4 gene that results in replacement of a conserved aspartic acid residue with glycine at position 299 in the extracellular domain of the TLR4 receptor. The Asp299Gly sequence variant occurred in 3 LPS responsive (5.8 %) and 7 LPS hyporesponsive (22.6 %) study subjects ($p=0.03$). Among the subjects with the common TLR4 allele (N=73), the dose-response slope (percent decline FEV₁/cumulative dose of inhaled LPS) averaged a 1.86 % decline in FEV₁/μg inhaled LPS (range 0.01 %-19.78 %), while the dose-response slope for the subjects with the Asp299Gly allele (N=10) was significantly less ($p=0.007$), averaging 0.59 % decline in FEV₁/μg inhaled LPS (range 0.00 %-1.59 %). Thus, a sequence polymorphism in the TLR4 gene, i.e., a missense mutation (Asp299Gly) in the fourth exon of the TLR4 gene, occurs in a substantial portion of the population, and is associated with an airway hyporesponsive in humans challenged with inhaled LPS. The allelic frequency of the A896G substitution was 6.6 % in the study population, 7.9 % in a normal control population from Iowa (Lidral et al., 1998), and 3.3 % in the parental chromosomes of the CEPH population (NIH-CEPH, 1992). As also described herein, the presence of a TLR4 mutation was associated with gram negative sepsis, severity of sepsis, pre-term delivery, and respiratory distress syndrome in pre-term infants.

The invention also provides an isolated and purified nucleic acid molecule comprising a nucleic acid segment, e.g., genomic DNA or cDNA, encoding TLR4, such as a variant TLR4. Also provided are primers, oligonucleotides and probes comprising the isolated nucleic acid sequences of the invention. The nucleic acid molecules of the invention may be single stranded or double stranded.

Transfection of CHO cells with either the wild-type or the mutant (Asp299Gly) allele of the TLR4 gene demonstrated that this mutation interrupts TLR4-mediated LPS signaling. Moreover, the wild-type allele of TLR4 rescues the LPS hyporesponsive phenotype in either airway epithelial cells or alveolar macrophages obtained from individuals with the TLR4 mutation. Thus, these results provide the first genetic evidence that a common mutation causes

differences in LPS responsiveness that may contribute to several disease states in humans.

Therefore, the invention further provides an expression cassette comprising a nucleic acid molecule of the invention, a host cell transformed with the expression cassette, and TLR4 polypeptides isolated therefrom. The transformed host cells, or isolated TLR4 polypeptides, may be useful in identifying agents that modulate, i.e., enhance or inhibit, TLR4 activity. For example, an expression cassette comprising a nucleic acid molecule of the invention which encodes a variant TLR4 polypeptide is introduced to murine 10 cells, e.g., oocytes via microinjection (see Sigmund et al., 1993). The resulting pups are screened for the presence of the nucleic acid molecule. Hence, the invention also provides a transgenic mouse, the genome of the cells of which is augmented with variant human TLR4 DNA. Human TLR4 transgenic mice of the invention have altered innate immunity, e.g., they are more susceptible to 15 gram negative sepsis than their nontransgenic counterparts.

The invention also provides a method to treat an individual at risk of, or having, an indication associated with altered innate immunity, in which an agent that alters TLR4 activity is administered to the individual.

20

Brief Description of the Figures

Figure 1. Genomic structure for the human TLR4 gene (exons are represented by boxes and introns are represented by lines). The coding sequence is in black and the nucleotides encoding the transmembrane domain (TM) are shaded. The positions of the introns in the published TLR4 cDNA sequence 25 (Rock et al., 1998; Genbank Accession No. U88880) are listed. The exon (caps) and intron (lower case) sequences at each of the splice junctions is shown (sequences at 5' and 3' splice junctions for intron 1, SEQ ID NO:1 and SEQ ID NO:63, respectively; for intron 2, SEQ ID NO:2 and SEQ ID NO:64, respectively; and for intron 3, SEQ ID NO:3 and SEQ ID NO:65, respectively).

30

Figure 2. The human TLR4 gene is alternatively spliced. Photographs are of agarose gels containing the products amplified from a multi-tissue cDNA panel from human adult (panel a; Clontech #K1420-1, Palo Alto, CA), and human fetal (panel b; Clontech #K1425-1, Palo Alto, CA) cDNA. The tissues

included brain (B), heart (H), kidney (K), liver (Li), lung (Lu), pancreas (Pa), placenta (Pl), skeletal muscle (Sk), spleen (Sp), and thymus (T). The first lane of each gel included a 100 bp molecular weight standard (MW). The forward and reverse PCR primers were derived from exons 1 and 4, respectively (see 5 panel c) and amplified three products of 453, 333, and 167 bp. The DNA sequence for these bands showed that both exons 2 and 3 were present in the 453 bp band, that exon 2 was absent in the 333 bp product, and that both exons 2 and 3 were absent in the 167 bp band. The 453 bp and 333 bp sequences are identical to previously published sequences for the human TLR cDNA 10 (Medzhitov et al., 1997; Rock et al., 1998). The open, closed, and shaded boxes indicate the untranslated, translated, and transmembrane domain portions of the TLR4 exons, respectively. The ends of the cDNAs were arbitrarily terminated at the stop codon (STP).

Figure 3. Mutations in the human TLR4 gene. The SSCV and sequence 15 analysis were performed blinded to the LPS response phenotype of the study subjects. The SSCV gel in panel a contains the products amplified from two samples that are homozygous for the 1060A allele (lanes 1 and 3), a heterozygous sample (lane 2) with both the 896A and 896G alleles, and a homozygous sample (lane 4) with only the 896G allele. The SSCV gel in panel 20 b contains the products amplified from a sample that is homozygous for the T allele at position -11 and the T allele at position 315 (lane 1), and from a sample that is heterozygous with a T and a deletion at position -11 and a T and a C allele at position 315. The nucleotide numbers are based on the previously published TLR4 cDNA sequence (Rock et al., 1998).

Figure 4. The aspartic acid residue at position 299 is conserved. A 25 portion of the predicted amino acid sequence is aligned for the TLR4 genes from human (Rock et al., 1998; SEQ ID NO:4), mouse (Poitorak et al., 1998; SEQ ID NO:5), rat (Genbank Accession No. AF057025; SEQ ID NO:6), and hamster (D. Golenbock, SEQ ID NO:7). The position of the first amino acid in each 30 sequence is given. The aspartic acid at position 299 is indicated with an arrow. Conserved amino acids are shaded.

Figure 5. Frequency distribution histogram of the dose-response slope (% decline in FEV₁/μg LPS). The % decline in FEV₁/μg LPS was calculated

following administration of the cumulative LPS dose that either resulted in at least a 20 % decline in FEV₁ or the decline in FEV₁ following a cumulative inhaled dose of 41.5 µg LPS. Subjects above the x-axis (solid bars) are homozygous for the 896A allele (WT/WT); subjects below the x-axis (open bars) are either heterozygous or homozygous (*) for the missense Asp299Gly allele.

5 The data is replotted in the inset after the values on the x-axis were log normalized. P values are presented for the comparison of the % decline in FEV₁/µg LPS between subjects with the WT/WT genotype (N=73) and those with at least one Asp299Gly allele (N=10) using absolute values (P=0.037) and

10 log normalized values (P=0.026). Since the distribution of the dose-response slope (% decline FEV₁/cumulative dose of inhaled LPS) was highly skewed, the two-sample Monte-Carlo permutation test based on 10,000 permutations was used to calculate P values (Fisher et al., 1993) the missense mutation (N=10) using absolute values (p=0.04) and the log normalized values (p=0.04) and the

15 log normalized values (p=0.025).

Figure 6. A) CHO/CD-14 cells that express the CD-14 receptor (generous gift of Doug Golenbock) were transfected with a wild-type or mutant TLR4 allele, and then exposed to LPS. Cells were co-transfected with a luciferase reporter construct. B) IL-1 α levels from airway epithelial cells of individuals which had been genotyped for TLR4. IL-1 α levels before and after LPS exposure are shown. C) IL-1 α levels from airway epithelial cells from a TLR4 heterozygote (WT/Asp299Gly). The cells were transduced with a recombinant adenovirus which expresses TLR4 (Rock et al., 1998), or a recombinant adenovirus which expresses green fluorescent protein (GFP), and then exposed to LPS. D) TNF- α levels from alveolar macrophage from a TLR4 homozygote (Asp299Gly/Asp299Gly). The cells were transduced with a recombinant adenovirus which expresses TLR4 (Rock et al., 1998), and then exposed to LPS.

Figure 7. Codons.

Figure 8. Exemplary amino acid substitutions.

30 Figure 9. A) A partial nucleotide sequence of genomic human TLR4 DNA (SEQ ID NO:62). B) The 5' UTR, exon 1 (nt 1100-1283), and a partial sequence of intron 1 (Genbank Accession No. AF172169; SEQ ID NO:70). C) Exon 2 (nt 192-311), exon 3 (nt 556-722), and intron 2 (244 bp) (Genbank

Accession No. AF172170; SEQ ID NO:71). D) Exon 4 (nt 1691-6172) and the 3' UTR (Genbank Accession No. AF172171; SEQ ID NO:72).

Detailed Description of the Invention

5 As used herein, the terms “isolated and/or purified” refer to *in vitro* preparation, isolation and/or purification of a nucleic acid molecule or polypeptide, so that it is not associated with *in vivo* substances. Thus, with respect to an “isolated nucleic acid molecule”, which includes a polynucleotide of genomic, cDNA, or synthetic origin or some combination thereof, the

10 “isolated nucleic acid molecule” (1) is not associated with all or a portion of a polynucleotide in which the “isolated nucleic acid molecule” is found in nature, (2) is operably linked to a polynucleotide which it is not linked to in nature, or (3) does not occur in nature as part of a larger sequence. An isolated nucleic acid molecule means a polymeric form of nucleotides of at least 10 bases in length,

15 either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide. The term includes single and double stranded forms of DNA. The term “oligonucleotide” referred to herein includes naturally occurring, and modified nucleotides linked together by naturally occurring, and non-naturally occurring oligonucleotide linkages. Oligonucleotides are a polynucleotide

20 subset with 200 bases or fewer in length. Preferably, oligonucleotides are 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19, or 20 to 40 bases in length. Oligonucleotides are usually single stranded, e.g., for primers or probes; although oligonucleotides may be double stranded, e.g., for use in the construction of a variant. Oligonucleotides of the invention can be either sense

25 or antisense oligonucleotides. The term “naturally occurring nucleotides” referred to herein includes deoxyribonucleotides and ribonucleotides. The term “modified nucleotides” referred to herein includes nucleotides with modified or substituted sugar groups and the like. The term “oligonucleotide linkages” referred to herein includes oligonucleotides linkages such as phosphorothioate,

30 phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate, phosphoroamidate, and the like. An oligonucleotide can include a label for detection, if desired.

The term "isolated polypeptide" means a polypeptide encoded by genomic DNA, cDNA or recombinant RNA, or is synthetic origin, or some combination thereof, which isolated polypeptide (1) is not associated with proteins found in nature, (2) is free of other proteins from the same source, e.g., 5 free of human proteins, (3) is expressed by a cell from a different species, or (4) does not occur in nature.

The term "sequence homology" means the proportion of base matches between two nucleic acid sequences or the proportion amino acid matches between two amino acid sequences. When sequence homology is expressed as a 10 percentage, e.g., 50 %, the percentage denotes the proportion of matches over the length of sequence from one TLR4 allele that is compared to another TLR4 allele. Gaps (in either of the two sequences) are permitted to maximize matching; gap lengths of 15 bases or less are usually used, 6 bases or less are preferred with 2 bases or less more preferred. When using oligonucleotides as 15 probes or treatments, the sequence homology between the target nucleic acid and the oligonucleotide sequence is generally not less than 17 target base matches out of 20 possible oligonucleotide base pair matches (85 %); preferably not less than 9 matches out of 10 possible base pair matches (90 %), and more preferably not less than 19 matches out of 20 possible base pair matches (95 %).

20 The term "selectively hybridize" means to detectably and specifically bind. Polynucleotides, oligonucleotides and fragments of the invention selectively hybridize to nucleic acid strands under hybridization and wash conditions that minimize appreciable amounts of detectable binding to nonspecific nucleic acids. High stringency conditions can be used to achieve 25 selective hybridization conditions as known in the art and discussed herein. Generally, the nucleic acid sequence homology between the polynucleotides, oligonucleotides, and fragments of the invention and a nucleic acid sequence of interest is at least 65 %, and more typically with preferably increasing homologies of at least about 70 %, about 90 %, about 95 %, about 98 %, and 100 30 %.

Two amino acid sequences are homologous if there is a partial or complete identity between their sequences. For example, 85 % homology means that 85 % of the amino acids are identical when the two sequences are aligned

for maximum matching. Gaps (in either of the two sequences being matched) are allowed in maximizing matching; gap lengths of 5 or less are preferred with 2 or less being more preferred. Alternatively and preferably, two protein sequences (or polypeptide sequences derived from them of at least 30 amino acids in length) are homologous, as this term is used herein, if they have an alignment score of at more than 5 (in standard deviation units) using the program ALIGN with the mutation data matrix and a gap penalty of 6 or greater. See Dayhoff, M. O., in *Atlas of Protein Sequence and Structure*, 1972, volume 5, National Biomedical Research Foundation, pp. 101-110, and Supplement 2 to this volume, pp. 1-10. The two sequences or parts thereof are more preferably homologous if their amino acids are greater than or equal to 50 % identical when optimally aligned using the ALIGN program.

The term "corresponds to" is used herein to mean that a polynucleotide sequence is homologous (i.e., is identical, not strictly evolutionarily related) to all or a portion of a reference polynucleotide sequence, or that a polypeptide sequence is identical to a reference polypeptide sequence. In contradistinction, the term "complementary to" is used herein to mean that the complementary sequence is homologous to all or a portion of a reference polynucleotide sequence. For illustration, the nucleotide sequence "TATAC" corresponds to a reference sequence "TATAC" and is complementary to a reference sequence "GTATA".

The following terms are used to describe the sequence relationships between two or more polynucleotides: "reference sequence", "comparison window", "sequence identity", "percentage of sequence identity", and "substantial identity". A "reference sequence" is a defined sequence used as a basis for a sequence comparison; a reference sequence may be a subset of a larger sequence, for example, as a segment of a full-length cDNA or gene sequence given in a sequence listing, or may comprise a complete cDNA or gene sequence. Generally, a reference sequence is at least 20 nucleotides in length, frequently at least 25 nucleotides in length, and often at least 50 nucleotides in length. Since two polynucleotides may each (1) comprise a sequence (i.e., a portion of the complete polynucleotide sequence) that is similar between the two polynucleotides, and (2) may further comprise a sequence that is divergent

between the two polynucleotides, sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two polynucleotides over a “comparison window” to identify and compare local regions of sequence similarity.

5 A “comparison window”, as used herein, refers to a conceptual segment of at least 20 contiguous nucleotides and wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) of 20 percent or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the

10 two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith and Waterman (1981) *Adv. Appl. Math.* 2: 482, by the homology alignment algorithm of Needleman and Wunsch (1970) *J. Mol. Biol.* 48: 443, by the search for similarity method of Pearson and Lipman (1988) *Proc. Natl. Acad. Sci.*

15 (U.S.A.) 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by inspection, and the best alignment (i.e., resulting in the highest percentage of homology over the comparison window) generated by the various methods is

20 selected.

The term “sequence identity” means that two polynucleotide sequences are identical (i.e., on a nucleotide-by-nucleotide basis) over the window of comparison. The term “percentage of sequence identity” means that two polynucleotide sequences are identical (i.e., on a nucleotide-by-nucleotide basis) over the window of comparison. The term “percentage of sequence identity” is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total

25 number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The terms “substantial identity” as used herein denote a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that

30

has at least 85 percent sequence identity, preferably at least 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison window of at least 20 nucleotide positions, frequently over a window of at least 20-50 nucleotides,

5 wherein the percentage of sequence identity is calculated by comparing the reference sequence to the polynucleotide sequence which may include deletions or additions which total 20 percent or less of the reference sequence over the window of comparison.

As applied to polypeptides, the term "substantial identity" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least about 80 percent sequence identity, preferably at least about 90 percent sequence identity, more preferably at least about 95 percent sequence identity, and most preferably at least about 99 percent sequence identity.

10

15 As used herein, "substantially pure" means an object species is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition), and preferably a substantially purified fraction is a composition wherein the object species comprises at least about 50 percent (on a molar basis) of all macromolecular species present.

20 Generally, a substantially pure composition will comprise more than about 80 percent of all macromolecular species present in the composition, more preferably more than about 85 %, about 90 %, about 95 %, and about 99 %. Most preferably, the object species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional

25 detection methods) wherein the composition consists essentially of a single macromolecular species.

An isolated "variant" TLR4 polypeptide has at least 50 %, preferably at least about 80 %, and more preferably at least about 90 %, but less than 100 %, contiguous amino acid sequence homology or identity to the amino acid sequence of a reference (wild-type) TLR4 polypeptide. Preferably, the TLR4 polypeptides of the invention are biologically active. Biologically active polypeptides include those that induce an immune response when administered to an organism, are bound by antibodies specific for TLR4, activate signaling

through NF-KB and AP-1, interact with CD14, or induce cytokine release following LPS stimulation. While it is preferred that a variant TLR4 has at least about 0.1%, preferably at least about 1%, and more preferably at least about 10%, of the activity of wild-type TLR4, the invention includes variant TLR4

5 polypeptides having no detectable biological activity. Likewise, a “variant” TLR4 nucleic acid molecule has at least about 80%, preferably at least about 90% and more preferably at least about 95%, but less than 100% contiguous nucleic acid sequence homology or identity to the nucleic acid sequence of a wild-type TLR4 gene.

10 As used herein, an “indication or condition associated with aberrant, modified or altered innate immunity” includes, but is not limited to, hyporesponsiveness to LPS, susceptibility to infection with gram-negative bacteria, susceptibility to sepsis by gram-negative bacteria, susceptibility to chronic airway disease, susceptibility to asthma, susceptibility to arthritis,

15 susceptibility to pyelonephritis, susceptibility to gall bladder disease, susceptibility to pneumonia, susceptibility to bronchitis, susceptibility to chronic obstructive pulmonary disease, severity of cystic fibrosis, and susceptibility to local and systemic inflammatory conditions, e.g., systemic inflammatory response syndrome (SIRS), local gram negative bacterial infection, or acute

20 respiratory distress syndrome (ARDS).

A. Nucleic Acid Molecules of the Invention

1. Sources of the Nucleic Acid Molecules of the Invention

Sources of nucleotide sequences from which the present nucleic acid

25 molecules encoding TLR4, a portion (fragment) thereof, a variant thereof or the nucleic acid complement thereof, include total or polyA⁺ RNA from any mammalian, preferably human, cellular source from which cDNAs can be derived by methods known in the art. Other sources of the DNA molecules of the invention include genomic libraries derived from any mammalian cellular

30 source. Moreover, the present DNA molecules may be prepared *in vitro*, e.g., by synthesizing an oligonucleotide of about 100, preferably about 75, more preferably about 50, and even more preferably about 40, nucleotides in length, or by subcloning a portion of a DNA segment that encodes a particular TLR4.

2. Isolation of a Gene Encoding TLR4

A nucleic acid molecule encoding TLR4 can be identified and isolated using standard methods, as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, NY (1989). For example, reverse-transcriptase PCR (RT-PCR) can be employed to isolate and clone TLR4 cDNAs. Oligo-dT can be employed as a primer in a reverse transcriptase reaction to prepare first-strand cDNAs from isolated RNA which contains RNA sequences of interest, e.g., total RNA isolated from human tissue. RNA can be isolated by methods known to the art, e.g., using TRIZOL™ reagent (GIBCO-BRL/Life Technologies, Gaithersburg, MD). Resultant first-strand cDNAs are then amplified in PCR reactions.

"Polymerase chain reaction" or "PCR" refers to a procedure or technique in which amounts of a preselected fragment of nucleic acid, RNA and/or DNA, are amplified as described in U.S. Patent No. 4,683,195. Generally, sequence information from the ends of the region of interest or beyond is employed to design oligonucleotide primers comprising at least 7-8 nucleotides. These primers will be identical or similar in sequence to opposite strands of the template to be amplified. PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genomic DNA, and cDNA transcribed from total cellular RNA, bacteriophage or plasmid sequences, and the like. See generally Mullis et al., Cold Spring Harbor Symp. Quant. Biol., 51, 263 (1987); Erlich, ed., PCR Technology, (Stockton Press, NY, 1989). Thus, PCR-based cloning approaches rely upon conserved sequences deduced from alignments of related gene or polypeptide sequences.

Primers are made to correspond to highly conserved regions of polypeptides or nucleotide sequences which were identified and compared to generate the primers, e.g., by a sequence comparison of other mammalian TLR4. One primer is prepared which is predicted to anneal to the antisense strand, and another primer prepared which is predicted to anneal to the sense strand, of a DNA molecule which encodes TLR4.

The products of each PCR reaction are separated via an agarose gel and all consistently amplified products are gel-purified and cloned directly into a suitable vector, such as a known plasmid vector. The resultant plasmids are

subjected to restriction endonuclease and dideoxy sequencing of double-stranded plasmid DNAs.

Another approach to identify, isolate and clone cDNAs which encode TLR4 is to screen a cDNA or genomic library. Screening for DNA fragments 5 that encode all or a portion of a DNA encoding TLR4 can be accomplished by probing the library with a probe which has sequences that are highly conserved between genes believed to be related to TLR4, e.g., the homolog of a particular TLR4 from a different species, or by screening of plaques for binding to antibodies that specifically recognize TLR4. DNA fragments that bind to a 10 probe having sequences which are related to TLR4, or which are immunoreactive with antibodies to TLR4, can be subcloned into a suitable vector and sequenced and/or used as probes to identify other cDNAs encoding all or a portion of TLR4.

Thus, "isolated and/or purified TLR4" nucleic acid refers to *in vitro* 15 isolation of a nucleic acid molecule from its natural cellular environment, and from association with other components of the cell, such as nucleic acid or polypeptide, so that it can be sequenced, replicated, and/or expressed. For example, "isolated TLR4 nucleic acid" is RNA or DNA containing greater than 9, preferably 36, and more preferably 45 or more, sequential nucleotide bases 20 that encode at least a portion of TLR4, a variant thereof, RNA or DNA complementary thereto, or which hybridizes to, RNA or DNA comprising TLR4 sequences, and remains stably bound under stringent conditions, as defined by methods well known in the art, e.g., in Sambrook et al., *supra*. Thus, the RNA or DNA is "isolated" in that it is free from at least one contaminating nucleic 25 acid with which it is normally associated in the natural source of the RNA or DNA and is preferably substantially free of any other mammalian RNA or DNA. The phrase "free from at least one contaminating source nucleic acid with which it is normally associated" includes the case where the nucleic acid is reintroduced into the source or natural cell but is in a different chromosomal location or is 30 otherwise flanked by nucleic acid sequences not normally found in the source cell.

As used herein, the term "recombinant nucleic acid", e.g., "recombinant DNA sequence or segment", refers to a nucleic acid, e.g., to DNA, that has been

derived or isolated from any appropriate tissue source, that may be subsequently chemically altered *in vitro*, so that its sequence is not naturally occurring, or corresponds to naturally occurring sequences that are not positioned as they would be positioned in a genome which has not been transformed with

5 exogenous DNA. An example of DNA "derived" from a source, would be a DNA sequence that is identified as a useful fragment within a given organism, and which is then chemically synthesized in essentially pure form. An example of such DNA "isolated" from a source would be a useful DNA sequence that is excised or removed from said source by chemical means, e.g., by the use of

10 restriction endonucleases, so that it can be further manipulated, e.g., amplified, for use in the invention, by the methodology of genetic engineering.

Thus, recovery or isolation of a given fragment of DNA from a restriction digest can employ separation of the digest on polyacrylamide or agarose gel by electrophoresis, identification of the fragment of interest by comparison of its

15 mobility versus that of marker DNA fragments of known molecular weight, removal of the gel section containing the desired fragment, and separation of the gel from DNA. See Lawn et al., *Nucleic Acids Res.*, 9, 6103 (1981), and Goeddel et al., *Nucleic Acids Res.*, 8, 4057 (1980). Therefore, "isolated DNA" includes completely synthetic DNA sequences, semi-synthetic DNA sequences,

20 DNA sequences isolated from biological sources, and DNA sequences derived from RNA, as well as mixtures thereof.

As used herein, the term "derived" with respect to a RNA molecule means that the RNA molecule has complementary sequence identity to a particular DNA molecule.

25 3. Variants of the Nucleic Acid Molecules of the Invention

Nucleic acid molecules encoding amino acid sequence variants of TLR4 are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of TLR4 nucleic acid.

Oligonucleotide-mediated mutagenesis is a preferred method for preparing amino acid substitution variants of TLR4. This technique is well known in the art as described by Adelman et al., DNA, 2, 183 (1983). Briefly, TLR4 DNA is altered by hybridizing an oligonucleotide encoding the desired 5 mutation to a DNA template, where the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence of TLR4. After hybridization, a DNA polymerase is used to synthesize an entire second complementary strand of the template that will thus incorporate the oligonucleotide primer, and will code for the selected alteration in the TLR4 10 DNA.

Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the 15 single-stranded DNA template molecule. The oligonucleotides are readily synthesized using techniques known in the art such as that described by Crea et al., Proc. Natl. Acad. Sci. U.S.A., 75, 5765 (1978).

The DNA template can be generated by those vectors that are either derived from bacteriophage M13 vectors (the commercially available M13mp18 20 and M13mp19 vectors are suitable), or those vectors that contain a single-stranded phage origin of replication as described by Viera et al., Meth. Enzymol., 153, 3 (1987). Thus, the DNA that is to be mutated may be inserted into one of these vectors to generate single-stranded template. Production of the single-stranded template is described in Sections 4.21-4.41 of Sambrook et al., 25 Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory Press, N.Y. 1989).

Alternatively, single-stranded DNA template may be generated by denaturing double-stranded plasmid (or other) DNA using standard techniques.

For alteration of the native DNA sequence (to generate amino acid 30 sequence variants, for example), the oligonucleotide is hybridized to the single-stranded template under suitable hybridization conditions. A DNA polymerizing enzyme, usually the Klenow fragment of DNA polymerase I, is then added to synthesize the complementary strand of the template using the oligonucleotide as

a primer for synthesis. A heteroduplex molecule is thus formed such that one strand of DNA encodes the mutated form of TLR4, and the other strand (the original template) encodes the native, unaltered sequence of TLR4. This heteroduplex molecule is then transformed into a suitable host cell, usually a 5 prokaryote such as *E. coli* JM101. After the cells are grown, they are plated onto agarose plates and screened using the oligonucleotide primer radiolabeled with 32-phosphate to identify the bacterial colonies that contain the mutated DNA. The mutated region is then removed and placed in an appropriate vector for peptide or polypeptide production, generally an expression vector of the type 10 typically employed for transformation of an appropriate host.

The method described immediately above may be modified such that a homoduplex molecule is created wherein both strands of the plasmid contain the mutations(s). The modifications are as follows: The single-stranded oligonucleotide is annealed to the single-stranded template as described above. 15 A mixture of three deoxyribonucleotides, deoxyriboadenosine (dATP), deoxyriboguanosine (dGTP), and deoxyribothymidine (dTTP), is combined with a modified thiodeoxyribocytosine called dCTP-(α S) (which can be obtained from the Amersham Corporation). This mixture is added to the template-oligonucleotide complex. Upon addition of DNA polymerase to this mixture, a 20 strand of DNA identical to the template except for the mutated bases is generated. In addition, this new strand of DNA will contain dCTP-(α S) instead of dCTP, which serves to protect it from restriction endonuclease digestion.

After the template strand of the double-stranded heteroduplex is nicked with an appropriate restriction enzyme, the template strand can be digested with 25 ExoIII nuclease or another appropriate nuclease past the region that contains the site(s) to be mutagenized. The reaction is then stopped to leave a molecule that is only partially single-stranded. A complete double-stranded DNA homoduplex is then formed using DNA polymerase in the presence of all four deoxyribonucleotide triphosphates, ATP, and DNA ligase. This homoduplex 30 molecule can then be transformed into a suitable host cell such as *E. coli* JM101.

For example, a preferred embodiment of the invention is an isolated and purified DNA molecule comprising a human DNA segment encoding a variant TLR4 having a nucleotide substitution at position 896 (A896G) which encodes

an amino acid substitution (Asp299Gly). Other nucleotide substitutions which result in silent mutations, missense mutations, or a nonsense mutations, can be ascertained by reference to Figure 7, Figure 8 and page D1 in Appendix D in Sambrook et al., *Molecular Cloning: A Laboratory Manual* (1989).

5 **B. Chimeric Expression Cassettes**

To prepare expression cassettes for transformation herein, the recombinant DNA sequence or segment may be circular or linear, double-stranded or single-stranded. A DNA sequence which encodes an RNA sequence that is substantially complementary to a mRNA sequence encoding TLR4 is 10 typically a "sense" DNA sequence cloned into a cassette in the opposite orientation (i.e., 3' to 5' rather than 5' to 3'). Generally, the DNA sequence or segment is in the form of chimeric DNA, such as plasmid DNA, that can also contain coding regions flanked by control sequences which promote the expression of the DNA present in the resultant cell line.

15 As used herein, "chimeric" means that a vector comprises DNA from at least two different species, or comprises DNA from the same species, which is linked or associated in a manner which does not occur in the "native" or wild type of the species.

Aside from DNA sequences that serve as transcription units for TLR4, or 20 portions thereof, a portion of the recombinant DNA may be untranscribed, serving a regulatory or a structural function. For example, the DNA may itself comprise a promoter that is active in mammalian cells, or may utilize a promoter already present in the genome that is the transformation target. Such promoters include the CMV promoter, as well as the SV40 late promoter and retroviral 25 LTRs (long terminal repeat elements), although many other promoter elements well known to the art may be employed in the practice of the invention.

Other elements functional in the host cells, such as introns, enhancers, polyadenylation sequences and the like, may also be a part of the DNA. Such elements may or may not be necessary for the function of the DNA, but may 30 provide improved expression of the DNA by affecting transcription, stability of the mRNA, or the like. Such elements may be included in the DNA as desired to obtain the optimal performance of the transforming DNA in the cell.

"Control sequences" is defined to mean DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotic cells, for example, include a promoter, and optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

"Operably linked" is defined to mean that the nucleic acids are placed in a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a peptide or polypeptide if it is expressed as a preprotein that participates in the secretion of the peptide or polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accord with conventional practice.

The DNA to be introduced into the cells further will generally contain either a selectable marker gene or a reporter gene or both to facilitate identification and selection of transformed cells from the population of cells sought to be transformed. Alternatively, the selectable marker may be carried on a separate piece of DNA and used in a co-transformation procedure. Both selectable markers and reporter genes may be flanked with appropriate regulatory sequences to enable expression in the host cells. Useful selectable markers are well known in the art and include, for example, antibiotic and herbicide-resistance genes, such as *neo*, *hpt*, *dhfr*, *bar*, *aroA*, *dapA* and the like. See also, the genes listed on Table 1 of Lundquist et al. (U.S. Patent No. 5,848,956).

Reporter genes are used for identifying potentially transformed cells and for evaluating the functionality of regulatory sequences. Reporter genes which encode for easily assayable proteins are well known in the art. In general, a

reporter gene is a gene which is not present in or expressed by the recipient organism or tissue and which encodes a protein whose expression is manifested by some easily detectable property, e.g., enzymatic activity. Preferred genes include the chloramphenicol acetyl transferase gene (*cat*) from Tn9 of *E. coli*, the 5 beta-glucuronidase gene (*gus*) of the *uidA* locus of *E. coli*, and the luciferase *luc* gene from firefly *Photinus pyralis*. Expression of the reporter gene is assayed at a suitable time after the DNA has been introduced into the recipient cells.

The general methods for constructing recombinant DNA which can transform target cells are well known to those skilled in the art, and the same 10 compositions and methods of construction may be utilized to produce the DNA useful herein. For example, J. Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2d ed., 1989), provides suitable methods of construction.

C. Transformation into Host Cells

15 The recombinant DNA can be readily introduced into the host cells, e.g., mammalian, bacterial, yeast or insect cells by transfection with an expression vector comprising DNA encoding TLR4 or its complement, by any procedure useful for the introduction into a particular cell, e.g., physical or biological methods, to yield a transformed cell having the recombinant DNA stably 20 integrated into its genome, so that the DNA molecules, sequences, or segments, of the present invention are expressed by the host cell.

Physical methods to introduce a DNA into a host cell include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like. Biological methods to introduce the DNA of 25 interest into a host cell include the use of DNA and RNA viral vectors. The main advantage of physical methods is that they are not associated with pathological or oncogenic processes of viruses. However, they are less precise, often resulting in multiple copy insertions, random integration, disruption of foreign and endogenous gene sequences, and unpredictable expression. Viral 30 vectors, useful to introduce genes to mammalian cells include, but are not limited to, poxvirus vectors, herpes simplex virus I vectors, adenovirus vectors, adeno-associated virus vectors, and the like.

As used herein, the term "cell line" or "host cell" is intended to refer to well-characterized homogenous, biologically pure populations of cells. These cells may be eukaryotic cells that are neoplastic or which have been "immortalized" *in vitro* by methods known in the art, as well as primary cells, or 5 prokaryotic cells. The cell line or host cell is preferably of mammalian origin, but cell lines or host cells of non-mammalian origin may be employed, including plant, insect, yeast, fungal or bacterial sources. Generally, the DNA sequence is related to a DNA sequence which is resident in the genome of the host cell but is not expressed, or not highly expressed, or, alternatively, overexpressed.

10 "Transfected" or "transformed" is used herein to include any host cell or cell line, the genome of which has been altered or augmented by the presence of at least one DNA sequence, which DNA is also referred to in the art of genetic engineering as "heterologous DNA," "recombinant DNA," "exogenous DNA," "genetically engineered," "non-native," or "foreign DNA," wherein said DNA 15 was isolated and introduced into the genome of the host cell or cell line by the process of genetic engineering. The host cells of the present invention are typically produced by transfection with a DNA sequence in a plasmid expression vector, a viral expression vector, or as an isolated linear DNA sequence.

To confirm the presence of the DNA sequence in the host cell, a variety 20 of assays may be performed. Such assays include, for example, "molecular biological" assays well known to those of skill in the art, such as Southern and Northern blotting, RT-PCR and PCR; "biochemical" assays, such as detecting the presence or absence of a particular TLR4, e.g., by immunological means (ELISAs and Western blots) or by assays described herein.

25 To detect and quantitate RNA produced from introduced DNA segments, RT-PCR may be employed. In this application of PCR, it is first necessary to reverse transcribe RNA into DNA, using enzymes such as reverse transcriptase, and then through the use of conventional PCR techniques amplify the DNA. In most instances PCR techniques, while useful, will not demonstrate integrity of 30 the RNA product. Further information about the nature of the RNA product may be obtained by Northern blotting. This technique demonstrates the presence of an RNA species and gives information about the integrity of that RNA. The presence or absence of an RNA species can also be determined using dot or slot

blot Northern hybridizations. These techniques are modifications of Northern blotting and only demonstrate the presence or absence of an RNA species.

While Southern blotting and PCR may be used to detect the DNA segment in question, they do not provide information as to whether the DNA 5 segment is being expressed. Expression may be evaluated by specifically identifying the polypeptide products of the introduced DNA sequences or evaluating the phenotypic changes brought about by the expression of the introduced DNA segment in the host cell.

D. TLR4 polypeptides, variants, and derivatives thereof

10 The present isolated, purified TLR4 polypeptides, variants or derivatives thereof, can be synthesized *in vitro*, e.g., by the solid phase peptide synthetic method or by recombinant DNA approaches (see above). The solid phase peptide synthetic method is an established and widely used method, which is described in the following references: Stewart et al., Solid Phase Peptide

15 Synthesis, W. H. Freeman Co., San Francisco (1969); Merrifield, J. Am. Chem. Soc., 85 2149 (1963); Meienhofer in "Hormonal Proteins and Peptides," ed.; C.H. Li, Vol. 2 (Academic Press, 1973), pp. 48-267; Bavaay and Merrifield, "The Peptides," eds. E. Gross and F. Meienhofer, Vol. 2 (Academic Press, 1980) pp. 3-285; and Clark-Lewis et al., Meth. Enzymol., 287, 233 (1997). These

20 peptides can be further purified by fractionation on immunoaffinity or ion-exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on an anion-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; or ligand affinity chromatography.

25 Once isolated and characterized, derivatives, e.g., chemically derived derivatives, of a given TLR4 can be readily prepared. For example, amides of

the TLR4 or TLR4 variants of the present invention may also be prepared by techniques well known in the art for converting a carboxylic acid group or precursor, to an amide. A preferred method for amide formation at the C-

30 terminal carboxyl group is to cleave the peptide from a solid support with an appropriate amine, or to cleave in the presence of an alcohol, yielding an ester, followed by aminolysis with the desired amine.

Salts of carboxyl groups of a peptide or peptide variant of the invention may be prepared in the usual manner by contacting the peptide with one or more equivalents of a desired base such as, for example, a metallic hydroxide base, e.g., sodium hydroxide; a metal carbonate or bicarbonate base such as, for 5 example, sodium carbonate or sodium bicarbonate; or an amine base such as, for example, triethylamine, triethanolamine, and the like.

N-acyl derivatives of an amino group of the TLR4 or variant thereof may be prepared by utilizing an N-acyl protected amino acid for the final condensation, or by acylating a protected or unprotected peptide. O-acyl 10 derivatives may be prepared, for example, by acylation of a free hydroxy peptide or peptide resin. Either acylation may be carried out using standard acylating reagents such as acyl halides, anhydrides, acyl imidazoles, and the like. Both N- and O-acylation may be carried out together, if desired.

Formyl-methionine, pyroglutamine and trimethyl-alanine may be 15 substituted at the N-terminal residue of the peptide or peptide variant. Other amino-terminal modifications include aminoxyptenane modifications (see Simmons et al., *Science*, 276, 276 (1997)).

In addition, the amino acid sequence of TLR4 can be modified so as to result in a variant TLR4. The modification includes the substitution of at least 20 one amino acid residue in the polypeptide for another amino acid residue, including substitutions which utilize the D rather than L form, as well as other well known amino acid analogs, e.g., unnatural amino acids such as α , α -disubstituted amino acids, N-alkyl amino acids, lactic acid, and the like. These analogs include phosphoserine, phosphothreonine, phosphotyrosine, 25 hydroxyproline, gamma-carboxyglutamate; hippuric acid, octahydroindole-2-carboxylic acid, stating, 1,2,3,4,-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, citrulline, α -methyl-alanine, para-benzoyl-phenylalanine, phenylglycine, propargylglycine, sarcosine, ϵ -N,N,N-trimethyllysine, ϵ -N-acetyllysine, N-acetylsine, N-formylmethionine, 30 methylhistidine, 5-hydroxylysine, ω -N-methylarginine, and other similar amino acids and imino acids and tert-butylglycine.

Conservative amino acid substitutions include aspartic-glutamic as acidic amino acids; lysine/arginine/histidine as basic amino acids; leucine/isoleucine,

methionine/valine, alanine/valine as hydrophobic amino acids; serine/glycine/alanine/threonine as hydrophilic amino acids. Conservative amino acid substitution also includes groupings based on side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, 5 valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a 10 group of amino acids having sulfur-containing side chains is cysteine and methionine. For example, it is reasonable to expect that replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a major effect on the properties of the resulting variant 15 polypeptide. Whether an amino acid change results in a functional polypeptide can readily be determined by assaying the activity of the polypeptide variant. Such assays are described herein.

Conservative substitutions are shown in Figure 8 under the heading of exemplary substitutions. More preferred substitutions are under the heading of 20 preferred substitutions. After the substitutions are introduced, the variants are screened for biological activity.

Amino acid substitutions falling within the scope of the invention, are, in general, accomplished by selecting substitutions that do not differ significantly in their effect on maintaining (a) the structure of the peptide backbone in the area 25 of the substitution, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophilic: cys, ser, thr;
- 30 (3) acidic: asp, glu;
- (4) basic: asn, gln, his, lys, arg;
- (5) residues that influence chain orientation: gly, pro; and
- (6) aromatic: trp, tyr, phe.

The invention also envisions polypeptide variants with non-conservative substitutions. Non-conservative substitutions entail exchanging a member of one of the classes described above for another.

Acid addition salts of the polypeptide or variant polypeptide or of amino residues of the polypeptide or variant polypeptide may be prepared by contacting the polypeptide or amine with one or more equivalents of the desired inorganic or organic acid, such as, for example, hydrochloric acid. Esters of carboxyl groups of the polypeptides may also be prepared by any of the usual methods known in the art.

10 E. Methods of the Invention

The invention provides a method to diagnose individuals who are at a greater risk of deleterious consequences due to bacterial infection, e.g., the individuals may be more susceptible to infection by gram-negative bacteria, e.g., local gram-negative infection, more susceptible to sepsis induced by gram-negative bacteria, more susceptible to chronic airway disease, more susceptible to asthma, more susceptible to gall bladder disease, more susceptible to pyelonephritis, more susceptible to pneumonia, more susceptible to bronchitis, more susceptible to chronic obstructive pulmonary disease, more susceptible to arthritis, at higher risk for severe cystic fibrosis, and more susceptible to local and systemic inflammatory conditions such as systemic inflammatory response syndrome (SIRS), and acute respiratory distress syndrome (ARDS). The invention is also useful in the development of drugs that target the TLR4 gene product, e.g., increase or decrease the function of TLR4, especially the extracellular domain. These agents may thus be useful to prevent or ameliorate infection by gram-negative bacteria, prevent or ameliorate sepsis induced by gram-negative bacteria, prevent or ameliorate LPS-induced chronic airway disease in normal, cystic fibrosis and asthmatic populations, prevent or ameliorate arthritis, and prevent or ameliorate local and systemic inflammatory conditions such as SIRS and ARDS, particularly in individuals at risk for these indications or conditions.

The invention will be further described by the following non-limiting examples.

Example 1

Methods

Study Subjects. The study population consisted of 83 healthy adult volunteers (31 men, 52 women) aged 18-50. Exclusion criteria included any history of allergies, tobacco use, cardiac or pulmonary disease. After written informed consent was obtained, all subjects were screened with spirometry, inhalation challenge with histamine, skin testing for common aeroallergens, chest x-ray, and electrocardiogram. All participants had normal screening studies (including histamine PC₂₀ > 32 mg/ml), were on no medications (except birth control), and had no significant acute or chronic cardiopulmonary disease or occupational exposures.

Inhalation Challenge Protocol. All subjects were exposed by inhalation challenge to buffered sterile saline (HBSS) followed by increasing concentrations of LPS. The solutions were delivered via a DeVilbiss 646 nebulizer powered by compressed air at 30 psi (DeVilbiss Co., Somerset, PA) and a Rosenthal dosimeter (Laboratory for Applied Immunology, Baltimore, MD). After the HBSS, subsequent inhalations delivered in increasing doses of LPS according to the following schedule: 0.5 µg, 1.0 µg, 2.0 µg, 3.0 µg, 5.0 µg, 10 µg, and 20 µg. Thus, the entire protocol delivered a total of 41.5 µg of LPS.

Incremental LPS inhalation challenge. The incremental LPS inhalation challenge was performed as follows. The % decline in FEV₁/µg LPS was calculated following administration of the cumulative LPS dose that either resulted in at least a 20% decline in FEV₁ or the decline in FEV₁ following a cumulative inhaled dose of 41.5 µg of LPS. Subjects above the x-axis (solid bars in Figure 5) are homozygous for the wild type allele (WT/WT); subjects below the x-axis (open bars in Figure 5) are either heterozygous or homozygous (*) for the missense Asp299Gly allele. The data is replotted in the inset after the values for the dose-response slope were log normalized. P values are presented for the comparison of the % decline in FEV₁/µg LPS between subjects with the WT/WT genotype (N=73) and those with at least one Asp299Gly allele (N=10) using absolute values (P=0.037) and log normalized values (P=0.026). Since the distribution of the dose-response slope (% decline FEV₁/cumulative dose of inhaled LPS) was highly skewed, the two-sample Monte-Carlo permutation test

based on 10,000 permutations was used to calculate P values (Fisher et al., 1993). To assess the allelic frequency of TLR4 sequence variants, a well-characterized Iowa population (Lidral et al., 1998) and the Centre d'Etude du Polymorphisme Humain (CEPH) population (NIH-CEPIT, 1992) were screened
5 for specific sequence variants identified in the 83 study subjects.

Endotoxin. Solutions of endotoxin for inhalation were prepared according to a standard protocol using lyophilized *Escherichia coli* (serotype 0111:B4, Sigma Chemical Co., St. Louis, MO) LPS. These solutions of LPS were resuspended in sterile Hank's balanced salt solution (without calcium or magnesium) at a pH of
10 7.0 and filter sterilized. All solutions used for inhalation were tested for sterility (bacteria and fungi) and LPS content (*Limulus amebocyte lysate assay*, QCL-1000; Whittaker Bioproducts, Walkersville, MD) prior to separation into individual aliquots. These aliquots were stored immediately after preparation at -70°C until used.

15 Physiologic Measurements. A Spirotech (Atlanta, GA) S600 spirometer was used to assess pulmonary function; spirometry was performed using standards established by the American Thoracic Society. Subjects were positioned upright in a chair and were using noseclips. Baseline spirometry was recorded after inhalation of saline, and then 1, 10, 20, and 30 minutes following inhalation of
20 each dose of LPS, and compared with the post-saline baseline spirometry. If the study subject's FEV₁ was greater than 80 % of the baseline measurement at the final assessment (30 minutes post-saline), the inhalation challenge was continued and the next does of LPS was administered. The challenge test was terminated when any of the following criteria had been met: 1) the subject did not wish to
25 continue for any reason; 2) the subject's FEV₁ decreased 20 % or greater from baseline; or 3) a cumulative dose of 41.5 µg had been achieved. Of 84 subjects enrolled in the study, 1 subject withdrew prior to completion of the LPS inhalation challenge test, 52 subjects had at least a 20 % decline in the FEV₁ during the LPS inhalation challenge test, and 31 subjects inhaled a cumulative
30 dose of 41.5 µg of LPS and did not decrease their FEV₁ by 20 %.

Assignment of Phenotype. Study subjects were categorized as either "responsive" or "hyporesponsive" to inhaled LPS. In the course of previous investigations, a large number of study subjects have been exposed to inhaled

LPS (Jagielo et al., 1996; Deetz et al., 1997). In general, most healthy non-asthmatic study subjects develop airflow obstruction (FEV₁ ≤ 80 % of the pre-exposure value) when challenged with approximately 40 µg of LPS. Based on this and a standard approach to the definition of airway hyperreactivity (FEV₁ decline of 20 % from pre-exposure values) (Chai et al., 1975), subjects were categorized as "LPS responsive" if they decreased their FEV₁ by at least 20 % at any point during the LPS inhalation challenge, or "hyporesponsive" if they had < 20 % decline in their FEV₁ after inhaling a cumulative does of 41.5 µg of LPS.

5 Isolation of Genomic Clone. A human bacterial artificial chromosomal (BAC) library (Research Genetics; Huntsville, AL) was screened with two sets of primers (1F: 5'ATGGGGCATATCAGAGCCTA 3'; SEQ ID NO:8, IR: 5'GTCCAATGGGAAGTTCTCT 3'; SEQ ID NO:9, 2F: 5'TCATTGTCCTGCAGAAGGTG 3'; SEQ ID NO:10, and 2R: 5'CAGGGCTTTCTGAGTCGTC 3'; SEQ ID NO:11) derived from the human 10 TLR4 gene (Genbank Accession Nos. U88880 and U93091). These sets of primers amplified a 160 bp and 140 bp product, respectively. PCR reactions were prepared by combining the following components: 1 µl of PCR 10X buffer (100 mM Tris-HCl, pH 8.3, 500 mM KCl), 200 µM each of dCTP, dGTP, dATP, and dTTP, 0.25 µM of each primer, 0.2 U of *AmpliTaq* DNA polymerase (Perkin 15 Elmer; Norwalk, CT) and 1 µl of the library sample in a final volume of 10 µl. Thermal cycling was performed with an initial denaturation at 94°C for 3 minutes followed by 35 cycles comprising 94°C, 55°C, and 72°C steps of 30 seconds each and a final extension of 72°C for 5 minutes. PCR products were separated by electrophoresis on 2% agarose gels, stained with ethidium bromide 20 and visualized under UV light.

25 Mutation Detection. Genomic DNA was isolated from whole blood obtained from the study subjects using a rapid salt isolation procedure (Laitinen et al., 1994). Overlapping primer sets were designed across the coding sequence such that products did not exceed 250 bp (Table 1). Primers were derived from 30 flanking intronic sequences to include all splice sites. PCR reactions were prepared as described above except that 10-20 ng of genomic DNA was used at template. Amplification products were separated on non-denaturing, fan-cooled gels containing 5% acrylamide/bis (19:1), 0.5X TBE, and 2.5% glycerol for 3

hours at 20 W. A subset of PCR products were also run on MDE gels. The gels were subjected to silver staining and aberrant bands extracted from the gel, reamplified, and sequenced in both directions. To verify the sequence of the aberrant band, the same primers were used to amplify and sequence genomic

5 DNA from each subject. At least one individual without the aberrant band was also sequenced for comparison. Amplification products derived from the extracted DNA were purified using spin columns (Qiagen; Santa Clarita, CA) and DNA concentration determined by spectrophotometry. The DNA sequence was determined with a Model 377 automated DNA sequencer (Perkin Elmer;

10 Norwalk, CT).

Table 1. Primers for amplification of TLR4 coding region.

		Exon 5' NT ^a FORWARD PRIMER (5'-3')	5' NT ^a REVERSE PRIMER (5'-3')	SIZE (bp)
1	24	CTGCTCGGTCAAACGGTGAT ¹	+33 AGTCAGCTCCTCTGAACCTTC ²	206
2	-106	CAGCAAGCACGATATTGGAT ^{3,b}	+18 CGTGCTCAGCATTCTAACCT ^{4,b}	244
3	-53	GAGTTGGAGACCATGGCAT ⁵	+41 GAACACCTCACCTTGTGCAG ⁶	262
4	-52	GGTTCTTATTTCAGCAGAAAT ⁷	483 CTTGATAAGTCCAGAAAAGGCT ⁸	172
4	496	GGTGGCTGTGGAGACAAATC ⁹	691 CCGCAAGTCTGTGCATAAA ¹⁰	195
4	639	ACTTGGACCTTCCAGCAAC ¹¹	798 GTCAGCCTTATGAAGCCTAAITTC ¹²	159
4	751	CTTATCCAACCAGGTGCA ¹³	952 CAAATTGCAACAGGCCCTCTAGA ¹⁴	201
4	882	TGGGAGAATTAGAAATGAAGGA ¹⁵	1080 AAAGTCTTTTACCCCTTCAATAGTC ¹⁶	198
4	1032	TTTCCTCATTTCCCTGGTGA ¹⁷	1161 AGAGATTGAGTTCAATGTGGG ¹⁸	129
4	1129	TGGACAGTTCACATTGA ¹⁹	1309 CTTTAGGCTGGTTGTCCCCAA ²⁰	180
4	1262	TTCAAAGGTTGCTGTCTCAA ²¹	1426 TGAAAACACTCACTTTGTTCAA ²²	164
4	1349	TCAAACCTCTGGGCTTAGAAC ²³	1526 CTTCGAGACTGGACAAAGCCA ²⁴	177
4	1480	CAGAGTTGGTTCAATGGCA ²⁵	1614 GAGAGGTCCAGGAAGGTCAA ²⁶	134
4	1551	TCCAGGAAAACCTCTCCA ²⁷	1746 ACCTGGAGGGAGTTCAGACA ²⁸	195
4	1702	TTCATTGGATAACGTTTCC ²⁹	1905 AAGAGCTGCCCTGGTCCCT ³⁰	203
4	1863	ACCAGAGTTCCCTGCAATGG ³¹	2032 TACAAGCACACTGAGGGACCG ³²	169
4	1956	TGCCCTGTGCTGAGTTGAAT ³³	2100 TTATGCAGGCCAGCAAGAAG ³⁴	144
4	2013	CGGT CCTCAGTGTGCTTGT ³⁵	2208 GGAGGCACCCCTCTCTCAA ³⁶	195
4	2149	CCAGGATGAGGACTGGTAA ³⁷	2338 GCGGCTCTGGATGAAGTGCT ³⁸	189
4	2290	AAGCCGAAAGGTGATTGTTG ³⁹	2442 CTGAGCAGGGTCTCTCCAC ⁴⁰	152
4	2398	TATCATCTTCATTGTCCTGCAGA ⁴¹	2617 AGATGTTGCCTCCCTGCCAAT ⁴²	219
4	2406	TCATTGTCCTGCAGAAGGTG ⁴³	2548 CAGGGCTTTCTGAGTCGTC ⁴⁴	142
4	2529	GACGACTCAGAAAAGCCCTG ⁴⁵	2683 TGAACAAGTGGACCCAG ⁴⁶	154
4	2597	AATTGGCAGGAAGCAACATC ⁴⁷	2772 GATTAGCAGGCCCTGCATATCT ⁴⁸	175

^a relative to published cDNA sequence of Medzhitov et al. (1997), Genbank accession #U93091

^b relative to published cDNA sequence of Rock et al. (1997), Genbank Accession #U888880, since exon 2 is absent in #U93091.

A "-" indicates primer is within intron on the 5' side of amplified exon; a "+" indicates primer is on the 3' side.

¹ SEQ ID NO:12	¹³ SEQ ID NO:18	²⁵ SEQ ID NO:24	³⁷ SEQ ID NO:30
² SEQ ID NO:36	¹⁴ SEQ ID NO:42	²⁶ SEQ ID NO:48	³⁸ SEQ ID NO:54
³ SEQ ID NO:13	¹⁵ SEQ ID NO:19	²⁷ SEQ ID NO:25	³⁹ SEQ ID NO:31
⁴ SEQ ID NO:37	¹⁶ SEQ ID NO:43	²⁸ SEQ ID NO:49	⁴⁰ SEQ ID NO:55
⁵ SEQ ID NO:14	¹⁷ SEQ ID NO:20	²⁹ SEQ ID NO:26	⁴¹ SEQ ID NO:32
⁶ SEQ ID NO:38	¹⁸ SEQ ID NO:44	³⁰ SEQ ID NO:50	⁴² SEQ ID NO:56
⁷ SEQ ID NO:15	¹⁹ SEQ ID NO:21	³¹ SEQ ID NO:27	⁴³ SEQ ID NO:33
⁸ SEQ ID NO:39	²⁰ SEQ ID NO:45	³² SEQ ID NO:51	⁴⁴ SEQ ID NO:57
⁹ SEQ ID NO:16	²¹ SEQ ID NO:22	³³ SEQ ID NO:28	⁴⁵ SEQ ID NO:34
¹⁰ SEQ ID NO:40	²² SEQ ID NO:46	³⁴ SEQ ID NO:52	⁴⁶ SEQ ID NO:58
¹¹ SEQ ID NO:17	²³ SEQ ID NO:23	³⁵ SEQ ID NO:29	⁴⁷ SEQ ID NO:35
¹² SEQ ID NO:41	²⁴ SEQ ID NO:47	³⁶ SEQ ID NO:53	⁴⁸ SEQ ID NO:59

Multi-tissue cDNA Expression Screen. Human adult (Clontech #K1420-1; Palo Alto, CA) and fetal (Clontech #K1425-1; Palo Alto, CA) multi-tissue cDNA panels were screened by PCR using primers derived from exon 1 (forward; 5'GCTCACAGAACAGTGGAGA 3'; SEQ ID NO:60) and exon 4 (reverse; 5' TAGGCTCTGATATGCCCAT3'; SEQ ID NO:61) of the human TLR4 gene. These PCR experiments were performed in 10 µl reactions composed of 0.025 U/µl of DNA polymerase (BioXACT; BioLine; Reno, NV), 1.0 µM of each primer, 200 µM of each dNTP, 1 µl of 10X buffer supplied by the manufacturer, and 1 µl of the cDNA sample. PCR conditions were: 95°C for 2 minutes; cycles of 0.5 minutes at 94°C, 0.5 minutes at 55°C, and 1 minute at 68°C; followed by a final extension step for 10 minutes at 68°C. The amplified products were separated on a 2% agarose gel, stained with ethidium bromide, and visualized under UV light.

Statistical Analysis. The statistical analysis was designed to determine whether specific mutations in the TLR4 gene were associated with the airway hyporesponsiveness to inhaled LPS. A one-tailed test of statistical significance was employed (Fleiss, 1986). In a 2 X 2 analysis, a Fisher's one-tailed exact test was used to determine whether specific mutations of the TLR4 gene occurred more frequently in study subjects who were considered LPS hyporesponsive compared to those with a normal airway response to inhaled LPS. In addition, because of the nonparametric distribution of dose-response slope (percent decline FEV₁/cumulative dose of inhaled LPS), this outcome log was transformed and the Student's one-tailed T test (assuming unequal variances) was used to determine whether the dose-response slope was significantly less in subjects with a specific mutation of TLR4 compared to subjects with the common TLR4 allele.

Bioassays. Cells were maintained in F12 media supplemented with 10% fetal calf serum (Gibco, Rockville, MD), 2 mM L-glutamine, and 10,000 units penicillin/streptomycin, with 1 µg/ml of G418 as selective antibiotic. Cells were transfected with a mixture of 4 µg of DNA and 10 µl of Superfect (Qiagen, Valencia, CA) for a 35 mm² dish. The DNA mix consisted of 2 µg of DNA and 10 µg NFκB reporter plasmid encoding for the luciferase gene (Clontech, Palo Alto, CA) and 1 µg of each TLR4 (Medzhitov et al., 1997; Genbank #U93091)

expression plasmid (WT or Asp299Gly). If only one expression plasmid was used, empty vector pcDNA3.1⁺ was added to keep the DNA concentration constant. Twenty-four hours later the cells were stimulated with 100 ng/ml of LPS for 6 hours. Total luciferase activity was measured using a commercially available method (Tropix, Bedford, MA). Briefly, after rinsing with PBS, cells were removed from filters by incubation with 120 µl lysis buffer (25 mM Tris-phosphate, pH 7.8; 2 mM DTT; 2 mM 1, 2-diaminocyclohexane-N,N,N',N'-tetraacetic acid; 10% glycerol; and 1% Triton X-100) for 15 minutes. Light emission was quantified in a luminometer (Analytical Luminescence Laboratory, San Diego, CA).

Airway epithelial cells were obtained from trachea and bronchi of lungs removed for organ donation. Cells were genotyped for TLR4 and isolated by enzyme digestion as previously described (Zabner et al., 1996). Freshly isolated cells were seeded at a density of 5×10^5 cells/cm² onto collagen-coated, 0.6 cm² diameter millicell polycarbonate filters (Millipore Corp., Bedford, MA). The cells were maintained at 37°C in a humidified atmosphere of 5% CO₂ and air. Twenty-four hours after plating, the mucosal media was removed and the cells were allowed to grow at the air-liquid interface. The culture media consisted of a 1:1 mix of DMEM/Ham's F12, 5% Ultraser G (Biosepra SA, Cedex, France), 100 U/ml penicillin, 100 µg/ml streptomycin, 1% nonessential amino acids, and 0.12 U/ml insulin. Epithelia were tested for transepithelial resistance, and for morphology by scanning electron microscopy. Fourteen days after seeding, the basal release of IL-1 α was measured in WT/WT (12 specimens from 4 individuals) and WT/Asp299Gly (24 specimens from 4 individuals) epithelia by collecting the basolateral conditioned media after 24 hours (Figure 6b). The epithelia were then exposed to 100 ng/ml of LPS on the apical side for 6 hours, and the basolateral media was collected after 24 hours. IL-1 α was measured using a commercially available ELISA (R&D; Minneapolis, MN).

To rescue the LPS hyporesponsive phenotype, heterozygote (WT/Asp299Gly) airway epithelia (Figure 6c) or homozygote (Asp299Gly/Asp299Gly) alveolar macrophages (Figure 6d) were transfected with a recombinant adenovirus vector expressing TLR4 (Rock et al. 1998; Genbank #U88880) that was prepared as described previously (Dandson et al.,

1994) by the University of Iowa Gene Transfer Vector Core at titers of about 10^{10} infectious units (I.U.)/ml. Briefly TLR4 plasmid was blunt ended and cloned into the shuttle vector pAd5/CMVk-NpA using the EcoRV site. Fourteen days after seeding of the airway epithelia (20 specimens from 4 individuals), 5 MOI of the recombinant viruses (Ad/TLR4 and Ad/eGFP in phosphate buffered saline) were added to the basolateral surface of the epithelia for 30 minutes (Walters et al., 1999). After infection, the epithelia were incubated at 37°C for an additional 48 hours before the LPS stimulation assay. To assay for basal LPS response, the media was changed with fresh 500 µl of Ultroser G, and collected 10 after 24 hours to measure the basal IL-1 α secretion to the basolateral side. After collecting the basal specimen, the epithelia were exposed to 100 ng/ml of LPS on the apical side for 6 hours, and the media was collected after 24 hours. To assay for gene transfer efficiency, the epithelia was associated with 0.05% trypsin and 0.53 mM EDTA. Fluorescence from 50,000 individual cells was analyzed using 15 fluorescence-activated cell analysis (FACScan, Lysys II software, Becton Dickinson, San Jose, CA). The percentage of GFP positive cells ranged between 52% and 76%. Human alveolar macrophages were collected by BAL from a homozygote (Asp299Gly/Asp299Gly) study subject as previously described (Deetz et al., 1967). Macrophages were seeded onto a 96 well plate at a density 20 of 10^5 cells per well. The cells were infected after 4 hours with Ad/TLR4 in a CaPi coprecipitate (Lasbinder et al., 1998) at an MOI of 50, and a Ca $^{++}$ concentration of 16.8 mM. Sixteen hours after infection, the cells were exposed to LPS in 1% serum for 6 hours, and the media was collected. TNF- α was measured using a commercially available ELISA (R&D; Minneapolis, MN).

25 **Results**

Genomic Structure of the TLR4 Gene. To determine the genomic structure of the TLR4 gene, a bacterial artificial chromosome (BAC) library was screened by PCR with primers derived from the 5' and 3' ends of the cDNA sequence. Human BAC clone 439F3 was identified with both sets of primers and 30 sequenced to identify exon/intro splice sites using the two published cDNA sequences (Medzhitov et al., 1997; Rock et al., 1998). The TLR4 cDNA published by Medzhitov et al. (1997) (Genbank Accession No. U93091) was missing a 120 bp sequence beginning at nucleotide 136 of the other published

cDNA (Rock et al., 1998) (Genbank Accession No. U88880). Assuming this missing sequence represented an alternatively spliced exon, DNA sequencing primers were designed to amplify across the predicted splice junctions. When the genomic sequence (Figure 9) was compared to the cDNA sequences, the 5 exon/intron junctions were revealed (Figure 1). The human TLR4 gene is organized into 4 exons that span about 11 kb of genomic DNA. As predicted, the 120 bp sequence missing in the cDNA from Medzhitov et al. (1997) corresponds to exon 2.

To determine whether other exons may be revealed by additional splice 10 forms, a panel of cDNAs from adult (Figure 2a) and fetal (Figure 2b) tissues were examined with PCR primers designed to amplify all nucleotides between exons 1 and 4. In all adult and fetal tissues, three products were amplified (453, 333, and 167 bp), although their relative amounts varied. In addition to the 3' end of exon 1 and the 5' end of exon 4, the 453 bp product contained both exons 15 2 and 3, the 333 bp product was missing exon 2, and the 167 bp product was missing both exons 2 and 3 (Figure 2c). The 453 and 333 bp products are identical to the published cDNA sequences (Medzhitov et al., 1997; Rock et al., 1998), and confirm that no other exons are present for the human TLR4 gene. The 167 bp product depicts alternative splicing of exons 1 and 4, and represents 20 a novel TLR4 product. The nucleotide position of alleles are relative to the TLR4 cDNA sequence published by Medzhitov et al. (1997).

Mutation Analysis. SSCV was employed to detect sequence variants across the entire coding region of TLR4 gene in the 83 unrelated probands who completed the incremental LPS inhalation challenge test. When band shifts were detected 25 on SSCV analysis, the bands were sequenced to identify and confirm the sequence variants. The SSCV and sequence analysis were performed blinded to the LPS response phenotype of the study subjects. A band variant was detected by SSCV in 10 (12 %) of the 83 subjects, and direct sequencing detected an A to G substitution at nucleotide 896 of the published TLR4 cDNA (Figure 3a)

30 (Genbank Accession No. U88880). To confirm these findings, the 83 unrelated probands were sequenced in the forward and reverse directions with primers designed to amplify the 896 nucleotide; the same 10 individuals were found to have the A896G substitution and the remaining individuals were confirmed to

have the common TLR4 allele. Importantly, one of the 10 individuals with the A896G substitution was homozygous for this mutation and the remaining 9 had a single mutant allele. The allelic frequency of the A896G substitution was 6.6 % in the study population, 7.9 % in a normal control population from Iowa 5 (Lidral et al., 1998), and 3.3 % in the parental chromosomes of the CEPH population (NIH-CEPH, 1992).

The A896G substitution results in replacement of a conserved aspartic acid (A) residue with glycine (G) at amino acid 299 (Figure 4). This missense mutation (Asp299Gly) is in the fourth exon of TLR4 and is present in the 10 extracellular domain of this receptor. The region surrounding amino acid 299 appears to be in an alpha helical conformation (Gibrat et al., 1987). Replacement of the conserved aspartic acid with glycine at position 299 causes disruption of the alpha helical protein structure resulting in the formation of an extended beta strand (Gibrat et al., 1987).

15 Two other SSCV variants were identified in a single proband; a T to C change at nucleotide 479 (Figure 3b) and a deletion of a thymine nucleotide at position -11 in the third intron. The T479C variant did not alter the amino acid composition and is therefore considered a silent mutation. The T-11 variant did not alter the acceptor splice site, so the significance of this deletion is unknown.

20 The subject with these two sequence variants was responsive to inhaled LPS.

An additional missense mutation was identified within exon 4 of the TLR4 gene. This mutation results in the replacement of a threonine with an isoleucine residue at amino acid 399, which is on the 3' side of the previously identified Asp299Gly mutation. Both mutations are present within the 25 extracellular domain of the TLR4 protein. When the genotypes were compared with the phenotypes associated with endotoxin responsiveness, one individual who carried the Asp299Gly mutation did not carry the Thr399Ile mutation. Likewise, one individual who had the Thr399Ile mutation did not have the Asp299Gly mutation. Nine of the 83 volunteers carry both mutations. There 30 was a strong correlation between both of the TLR4 mutations and endotoxin hyporesponsiveness.

Phenotype/Genotype Analysis. Of the 83 unrelated study subjects who completed the LPS inhalation challenge test, 52 (63 %) were responsive to

inhaled LPS and 31 (37 %) were hyporesponsive to inhaled LPS. When the genotypes of these individuals were examined, the Asp299Gly sequence variant occurred in 3 LPS responsive (5.8 %) and 7 LPS hyporesponsive (22.6 %) study subjects ($P=0.029$). Among the subjects with the common TLR4 allele ($N = 73$),
5 the dose-response slope (percent decline $FEV_1/\mu\text{g}$ inhaled LPS) averaged 1.86 % decline in $FEV_1/\mu\text{g}$ inhaled LPS (range 0.01 %-19.78 %), while the dose-response slope for the subjects with the Asp299Gly allele ($N = 10$) was significantly less ($P=0.037$), averaging 0.59 % decline in $FEV_1/\mu\text{g}$ inhaled LPS (range 0.00 %-1.59 %) (Figure 5). This group difference in the dose-response
10 slope also exists on the log scale ($P=0.026$) where $\log(1 + \Delta FEV_1)$ was used since one individual has a ΔFEV_1 of 0.0. The subject who was homozygous for the Asp299Gly allele was hyporesponsive to inhaled LPS with a 0.28 % decline in $FEV_1/\mu\text{g}$ of inhaled LPS. This homozygote Asp299Gly subject is one of a monozygote twin pair; her twin sister was subsequently phenotyped and was also
15 found to be hyporesponsive to inhaled LPS with a 0.34% decline in $FEV_1/\mu\text{g}$ of inhaled LPS.

The biological significance of the Asp299Gly mutation was evaluated in several ways. First, transfection of CHO cells with either the WT or the mutant TLR4 gene demonstrated that the mutant allele does not respond normally to
20 LPS stimulation (Figure 6a). Second, airway epithelia obtained from heterozygote (WT/Asp299Gly) individuals do not respond to LPS stimulation (Figure 6b). Third, the wild-type allele of TLR4 clearly restored LPS responsiveness in either airway epithelial cells (Figure 6c) or alveolar macrophages (Figure 6d) obtained from individuals with the TLR4 mutation.

25 Discussion

The results described herein provide the first direct evidence to indicate that a sequence polymorphism in the TLR4 gene is associated with a hyporesponsive LPS phenotype in humans that interrupts LPS signaling. This conclusion is supported by the following findings: 1) unrelated subjects with the
30 Asp299Gly substitution were significantly less responsive to inhaled LPS than those homozygous for the common TLR4 allele; 2) an individual who was homozygous for the Asp299Gly substitution was hyporesponsive to inhaled LPS; 3) a monozygous twin pair, homozygous for the Asp299Gly substitution,

demonstrated a very similar response to inhaled LPS; and 4) *in vitro* studies demonstrate that mutant TLR4 does not respond to LPS stimulation. This conclusion is indirectly supported by the finding in C3H/HeJ mice where a point mutation in intracellular domain of *Tlr4* is also associated with LPS hyporesponsiveness (Poltorak et al., 1998; Qureshi et al., 1999). The identified Asp299Gly missense mutation is in the fourth exon of the TLR4 gene and, unlike the C3H/HeJ mutation, is located in the extracellular domain of this receptor. The findings described herein suggest that a specific region in the extracellular domain of TLR4 may play an important role in receptor function and regulation of the innate immune response to LPS in humans.

This discovery may have important ramifications for a broad spectrum of human diseases. First, the Asp299Gly TLR4 substitution is a relatively common mutation, potentially affecting the responsiveness of a substantial portion of the population to LPS. The allelic frequency of the Asp299Gly TLR4 substitution in the three populations screened was between 3.3 % and 7.9 %, and homozygous individuals were identified in each of the populations. Second, the results described herein provide further support for the role of TLR4 in LPS signaling. A fundamental understanding of LPS signaling will undoubtedly alter approaches to gram-negative sepsis, as well as other diseases thought to be mediated by endotoxin, such as the systemic inflammatory response syndrome (Wang et al., 1995), acute respiratory distress syndrome (Brigham et al., 1986), and asthma or other forms of airway disease caused (Rylander et al., 1989; Schwartz et al., 1995) or exacerbated (Schwartz et al., 1995; Michel et al., 1996) by endotoxin. Identification of the essential components of LPS signaling also provide new therapeutic targets for endotoxin mediated conditions. Third, the specific Asp299Gly TLR4 substitution may provide a simple screening mechanism to risk stratify a population. Identification of this mutation may lead to a better appreciation of the role of LPS responsiveness in a broad range of acquired and genetic disorders. For example, mutations of the TLR4 gene may explain why a minority of patients with gram-negative sepsis develop ARDS (Hudson et al., 1995) or why patients with cystic fibrosis and the identical CFTR mutation have different courses of disease (Veeze et al., 1994). Finally, it must be acknowledged that normal responsiveness to endotoxin is an important

component of innate immunity, and the Asp299Gly TLR4 substitution may prove to be associated with negative clinical outcomes. In fact, the C3H/HeJ mouse is more susceptible to *Salmonella typhimurium* (O'Brien et al., 1980), despite its resistance to LPS (Sultzler et al., 1968). Although individuals with the 5 Asp299Gly TLR4 substitution may be more resistant to localized forms of endotoxin-induced inflammation, these individuals may prove to be more susceptible to a systemic inflammatory response initiated or exacerbated by endotoxin.

The findings described herein demonstrate that a specific region in the 10 extracellular domain of TLR4 plays an important role in receptor function and regulation of the innate immune response to LPS in humans. The sequence variants reported thus far for mammalian, i.e., murine, TLR4 are located in the cytoplasmic domain (Poltorak et al., 1998; Qureshi et al., 1999). While it is logical to hypothesize that mutations in the cytoplasmic domain of TLR4 disrupt 15 the signaling pathway leading to activation of NF- κ B and AP-1 (Medzhitov et al., 1998), the potential mechanisms that are altered by mutations in extracellular domain of TLR4 are less obvious.

TLR4 is a transmembrane protein and it is therefore not surprising to find 20 a putative signal peptide at the N-terminus, presumably responsible for proper trafficking to the cell membrane (Medzhitov et al., 1997). This finding raises the possibility that sequence variants in the extracellular domain of TLR4 can disrupt trafficking of this receptor to the cell membrane and enhance proteolysis. There are several examples in the literature which show that the presence of a 25 single point mutation at a conserved amino acid can disrupt protein folding and specifically affect protein trafficking (Jackson et al., 1998; DeFranco et al., 1998). Mutations of this kind could give rise to a range of phenotypes from almost normal to completely unresponsive, depending on the severity of the trafficking defect. Another possible mechanism that may explain the association between a mutation in the extracellular domain of TLR4 and LPS responsiveness 30 is impairment of ligand binding to the extracellular domain. The extracellular domains of the toll proteins are clearly involved in the cellular response to LPS (Medzhitor et al., 1997; Yang et al., 1998). Yet, so far no convincing evidence has been found that the toll proteins are directly interacting with LPS (Wright,

1999). The discovery of an association between a mutation in the extracellular domain of TLR4 and a discernable LPS phenotype in humans should aid in clarifying whether the extracellular domain of this receptor is important for proper membrane localization of TLR4 and if LPS directly interacts with TLR4.

5 A final possibility is that the missense mutation of TLR4 affects its interaction with either an extracellular ligand or an intracellular protein (Wright, 1999). The extracellular domain of TLR4, and specifically the Asp299Gly amino acid change may provide a key therapeutic target to modulate LPS signaling.

TLR4 may be one of several factors that may regulate the airway response to inhaled LPS. Among the subjects with the Asp299Gly substitution, 10 7 were hyporesponsive to LPS and 3 developed airflow obstruction during the LPS inhalation challenge test. None of the subjects with this mutation were in the most sensitive quartile of the LPS responders. Although asthmatic patients were included because of their increased airway responsiveness to inhaled LPS (Michel et al., 1989), it remains possible that the 3 subjects with the Asp299Gly substitution who were responsive to inhaled LPS had some type of airway inflammation (e.g., early viral illness) that enhanced their response to inhaled LPS. Moreover, since 22.6 % of the study subjects who were hyporesponsive to LPS had at least one copy of the Asp299Gly TLR4 allele, other genes (or 15 possibly acquired conditions) may prove to play a role in modulating the biological response to LPS. For instance, TNF- α is one of the primary cytokines that mediates the toxic effects of LPS (Beutler et al., 1985). A polymorphism at -308 in the TNF- α promoter region results in higher constitutive and inducible levels of TNF- α (Wilson et al., 1997), and this polymorphism has been shown to 20 result in a worse outcome in children with either meningococcal disease (Nadel et al., 1996) or cerebral malaria (McGuire et al., 1994). Likewise, allelic variants of TLR4 receptors and their ligands appear to delay the progression of disease in patients with HIV infection (Mummidi et al., 1995). Thus, TLR4 appears to 25 represent only one of a number of genetic variants that may modulate the pathophysiologic response to LPS.

Example 2Methods

To genotype patients for TLR4, a PCR based RFLP assay was employed. For example, to detect point mutations in codon 299 such as those that result in

5 an amino acid substitutions at amino acid 299 (Asp (GAT) to Gly (GGT) change) and/or in codon 399 (Thr (ACC) to Ile (ATC) change), a primer spanning that codon and a second primer 3' or 5' to that primer are prepared.

Primers useful to detect a nucleotide change at codon 299 are: 299Forward primer (5' GATTAGCATACTTAGACTACTACCTCCATG 3'; SEQ ID

10 NO:66) and 299Reverse primer (5' GATCAACTCTGAAAAAGCATTCCCAC; SEQ ID NO:67). The underlined base in the forward primer fortuitously creates a NcoI (CCATGG) restriction site in the context of a mutation which is specific for carriers of the 299 mutation Asp to Gly. Primers useful to detect a nucleotide change at codon 399 include:

15 399Forward primer (5' GGTTGCTGTTCTCAAAGTGATTTGGG AGA A; SEQ ID NO:68) and 399Reverse Primer (5' ACCTGAAGACTGGAGAGTGAGTTAAATGCT; SEQ ID NO:69). The underlined base in the 399 Forward primer fortuitously creates a Hinfl restriction site (GANTC) in the context of a mutation which is specific for carriers of the

20 399 mutation Thr to Ile. The reverse primers were chosen at random based solely on such parameters as annealing temperature, expected product size and the like. Additional residues or fewer residues at the 5' end of the primers having the nucleotide change will not affect the outcome as long as the amplification conditions and reverse primers are chosen accordingly.

25 A MJ Tetrad PTC-225 Thermo cycler was used with both primer sets. For the 299 assay, primers at 10-100 pmole were mixed with 20 ng of genomic DNA, and Perkin Elmer Taq polymerase, deoxyribonucleotides and buffer according to the manufacturer's directions. Cycling conditions included an initial denaturation of 95°C, for 3 to 4 minutes, then 30 cycles of denaturation at

30 95°C for 30 seconds; annealing at 55°C for 30 seconds; and extension at 72°C for 30 seconds.

For the 399 assay, a Clontech Advantage amplification kit was used according to the manufacturer's directions. The cycling conditions included an

initial denaturation at 95°C for 3 to 4 minutes, then 30 cycles of denaturation at 95°C for 30 seconds; annealing at 55°C for 30 seconds; and extension at 72°C for 30 seconds.

Results

5 Septic shock remains a significant health concern world-wide and despite progress in understanding the physiologic and molecular basis of septic shock, the high mortality rate of septic shock patients remains unchanged. A common polymorphism in TLR4 was identified that is associated with hyporesponsiveness to inhaled endotoxin or lipopolysaccharide (LPS) in humans
10 (Example 1). Since TLR4 is a major receptor for LPS in mammals and Gram-negative bacteria are the prevalent pathogen associated with septic shock, these specific TLR4 alleles may be associated with a predisposition to or a more severe disease outcome for septic shock patients. Ninety-one septic shock patients as well as 83 healthy blood donor controls were genotyped for the
15 presence of the TLR4 Asp299Gly and TLR4 Thr399Ile mutations. The TLR4 Asp299Gly allele was found exclusively in septic shock patients ($P = 0.05$). Furthermore, septic shock patients with the TLR4 Asp299Gly allele had a significantly higher prevalence of Gram-negative infections. These findings suggest that the TLR4 Asp299Gly allele predisposes people to develop septic
20 shock with Gram-negative organisms.

In another study in a German population, the following observations were made: patients with TLR4 mutation(s) tended to have a longer ICU stay; patients with TLR4 mutation(s) were more prone to sepsis; and sepsis in patients with TLR4 mutation(s) was more severe than in patients that were wild-type for TLR4.
25

In a third study in a Finnish population, it was observed that mothers of pre-term infants and pre-term infants had a higher frequency of TLR4 mutation(s) than term infants. Also, infants with respiratory distress syndrome (RDS), particularly those born very prematurely, tended to have a higher
30 frequency of mutation(s) than premature infants without respiratory distress syndrome.

Thus, generally, the 299 mutation is slightly more prevalent than the 399 mutation, and in 90% of the cases, both mutations were observed. When only one mutation was found, it was more frequently the 299 mutation.

Thus, the presence of TLR4 mutations is associated with predisposition
5 to septic shock, severity of sepsis, pre-term delivery, and RDS in pre-term infants.

References

Beutler et al., Science, 229:869 (1985).

10 Bonner et al., Am. J. Respir. Cell Mol. Biol., 19:672 (1998).

Brigham et al., Am. Rev. Respir. Dis. 133:913 (1986).

Chai et al., J. Allergy Clin. Immunol., 56:323 (1975).

Chow et al., J. Biol. Chem., 274:10689 (1999).

Coutinho et al., Immunogenetics, 7:17 (1978).

15 Davidson et al., Exp. Neurol., 125:258 (1994).

Deetz et al., Am. J. Respir. Crit. Care Med., 155:254 (1997).

DeFranco et al., Prog. Clin. Biol. Res., 397:119 (1998).

De Franco et al., J. Steroid Biochem. Mol. Biol., 65:51 (1998).

Fasbender et al., J. Clin. Invest., 102:184 (1998).

20 Favorite et al., J. Clin. Invest., 21:589 (1942).

Fisher et al., Wiley, New York (1993).

Fleiss, J.C. The design and analysis of clinical experiments. New York:Wiley, 1986.

Gibrat et al., J. Mol. Biol., 198:425 (1987).

25 Hoshino et al., J. Immunol., 162:3749 (1999).

Hudson et al., Am. J. Respir. Crit. Care. Med., 151:293 (1995).

Jackson et al., Thromb. Haemost., 80:42 (1998).

Jagielo et al., Chest, 110:263 (1996).

Kuhns et al., J. Immunol., 158:3959 (1997).

30 Laitinen et al., Biotechniques, 17:316 (1994).

Lidral et al., Am. J. Hum. Genet., 63:557 (1998).

McGuire et al., Nature, 371:508 (1994).

Medzhitov et al., Cell, 91:295 (1997).

Medzhitov et al., Nature, 388:394 (1997).
Medzhitov et al., Mol. Cell., 2:253 (1998).
Michel et al., J. Appl. Physiol., 66:1059 (1989).
Michel et al., Rev. Respir. Dis., 146:352 (1992).
5 Michel et al., Am. J. Respir. Crit. Care Med., 154:1641 (1996).
Mummidi et al., Nat. Med., 4:786 (1998).
Nadel et al., J. Infect. Dis., 174:878 (1996).
NIH-CEPH (Collaborative Mapping Group), Science 258:67 (1992).
O'Brien et al., Nature, 287:440 (1980).
10 Poltorak et al., Blood Cells Mol. Dis., 24:340 (1998a).
Poltorak et al., Science, 282:2085 (1998).
Qureshi et al., J. Exp. Med., 189:615 (1999).
Rock et al., Proc. Natl. Acad. Sci. USA, 95:588 (1998).
Rylander et al., Am. Rev. Respir. Dis., 140:981 (1989).
15 Santamaria et al., J. Immunol., 143:913 (1989).
Schwartz et al., Am. J. Respir. Crit. Care. Med., 151:47 (1995a).
Schwartz et al., Am. J. Respir. Crit. Care. Med., 152:603 (1995b).
Sigmund et al., Hypertension, 22:599 (1993).
Sultzer, Nature, 219:1253 (1968).
20 Vogel et al., J. Immunol., 122:619 (1979).
Veeze et al., J. Clin. Invest., 93:461 (1994).
Walters et al., J. Biol. Chem., 274:10219 (1999).
Wang et al., Clin. Nucl. Med., 20:494 (1995).
Wilson et al., Proc. Natl. Acad. Sci. USA, 94:3195 (1997).
25 Wright et al., Science, 249:1431 (1990).
Wright et al., J. Exp. Med., 189:605 (1999).
Yang et al., Nature, 395:284 (1998).
Zabner et al., J. Virol., 70:6694 (1996).

30 All publications, patents and patent applications are incorporated herein by reference. While in the foregoing specification, this invention has been described in relation to certain preferred embodiments thereof, and many details have been set forth for purposes of illustration, it will be apparent to those skilled

in the art that the invention is susceptible to additional embodiments and that certain of the details herein may be varied considerably without departing from the basic principles of the invention.

WHAT IS CLAIMED IS:

1. An isolated and purified DNA molecule comprising a human genomic DNA segment encoding TLR4, a biologically active fragment or variant thereof.
2. The DNA molecule of claim 1 wherein the DNA segment encodes a variant TLR4.
3. The DNA molecule of claim 2 wherein the variant TLR4 has at least one amino acid substitution in the extracellular domain of TLR4.
4. The DNA molecule of claim 3 wherein the variant TLR4 comprises a glycine residue at position 299 or an isoleucine residue at position 399.
5. An isolated and purified nucleic acid molecule comprising a human nucleic acid segment encoding a variant TLR4, or a biologically active fragment thereof.
6. The nucleic acid molecule of claim 5 wherein the variant has at least one amino acid substitution in the extracellular domain of TLR4.
7. The nucleic acid molecule of claim 6 wherein the variant comprises a glycine residue at position 299 or an isoleucine residue at position 399.
8. An expression cassette comprising a promoter operably linked to a human DNA segment encoding a variant TLR4, or a biologically active fragment thereof.
9. The expression cassette of claim 8 wherein the variant TLR4 has at least one amino acid substitution in the extracellular domain of TLR4.

10. The expression cassette of claim 8 wherein the variant TLR4 comprises a glycine residue at position 299 or an isoleucine residue at position 399.
11. A host cell, the genome of which is augmented by the DNA molecule of claim 1.
12. A host cell, the genome of which is augmented by the nucleic acid molecule of claim 5.
13. A method to prepare a variant TLR4, comprising: culturing a host cell transformed with the nucleic acid molecule of claim 5 operably linked to a promoter, so that said host cell expresses the variant TLR4.
14. A method to prepare a variant TLR4, comprising: culturing a host cell transformed with the DNA molecule of claim 1 operably linked to a promoter, so that said host cell expresses the variant TLR4.
15. The method of claim 13 or 14 further comprising isolating TLR4 from the host cell.
16. A method of identifying a human at risk of, or having, an indication associated with altered innate immunity, comprising:
 - a) contacting an amount of DNA obtained from a human physiological sample with an amount of at least one TLR4-specific oligonucleotide under conditions effective to amplify the DNA so as to yield amplified DNA; and
 - b) detecting or determining whether the amplified DNA encodes at least a portion of a variant TLR4.
17. The method of claim 16 wherein the nucleic acid sample comprises genomic DNA.
18. The method of claim 16 wherein the nucleic acid sample is cDNA.

19. The method of claim 16 wherein the amplified DNA is subjected to electrophoresis in step b).
20. Isolated, variant human TLR4 polypeptide, or a biologically active fragment thereof.
21. The isolated polypeptide of claim 20 wherein the variant TLR4 has at least one amino acid substitution in the extracellular domain of TLR4.
22. The isolated polypeptide of claim 21 wherein the variant TLR4 comprises a glycine residue at position 299 or an isoleucine residue at position 399.
23. A method to identify an agent that alters TLR4 activity, comprising:
 - a) contacting a mammalian cell which expresses TLR4 with the agent; and
 - b) detecting or determining whether the agent alters TLR4 activity.
24. The method of claim 23 wherein the mammalian cell is transformed with a recombinant nucleic acid molecule encoding human TLR4.
25. An agent identified by the method of claim 24.
26. A method to alter TLR4 activity, comprising: contacting a mammalian cell with an agent effective to alter TLR4 activity.
27. The method of claim 26 wherein the mammalian cell is a human cell.
28. A method to detect a polymorphism in a human TLR4 gene, comprising: detecting or determining whether a nucleic acid sample obtained from a human comprises nucleic acid encoding variant TLR4.

29. A transgenic mouse whose cells comprise a chimeric DNA sequence, wherein the chimeric DNA sequence comprises a DNA segment encoding human TLR4, wherein the chimeric DNA sequence is integrated into the genome of the cells of the mouse, and wherein the DNA segment is expressed in the transgenic mouse so as to result in the transgenic mouse exhibiting altered innate immunity relative to a corresponding nontransgenic mouse.
30. The transgenic mouse of claim 29 wherein the DNA segment encodes a variant human TLR4.
31. The method of claim 16 wherein the TLR4-specific oligonucleotide comprises at least two nucleotide substitutions relative to the wild-type TLR4 nucleic acid sequence, which substitutions result in a restriction site that is not present in the wild-type TLR4 nucleic acid sequence and which restriction site is indicative of DNA that encodes a variant TLR4.
32. The method of claim 31 wherein the DNA encodes a variant TLR4 having an amino acid substitution at residue 299.
33. The method of claim 31 wherein the oligonucleotide comprises SEQ ID NO:66.
34. The method of claim 31 wherein the DNA encodes a variant TLR4 having an amino acid substitution at residue 399.
35. The method of claim 31 wherein the oligonucleotide comprises SEQ ID NO:68.

1

SEQUENCE LISTING

<110> University of Iowa Research Foundation

5 Schwartz, David A.
 Schutte, Brian C.

<120> Variant TLR4 nucleic acid and uses thereof

10<130> 875.010W01

<150> US 09/329,515

<151> 1999-06-10

15<160> 72

<170> FastSEQ for Windows Version 4.0

<210> 1

20<211> 28

<212> DNA

<213> Homo sapiens

<400> 1

25gcgtggaggt atgtggctgg agtcagct

28

<210> 2

<211> 28

<212> DNA

30<213> Homo sapiens

<400> 2

tcacggaggt tagaatgctg agcacgta

28

35<210> 3

<211> 28

<212> DNA

<213> Homo sapiens

40<400> 3

ttatccaggt aatgaatcca cttttaca

28

<210> 4

<211> 21

<212> PRT

<213> Homo sapiens

5

<400> 4

Leu Ala Tyr Leu Asp Tyr Tyr Leu Asp Asp Ile Ile Asp Leu Phe Asn

1

5

10

15

Cys Leu Thr Asn Val

10

20

<210> 5

<211> 20

<212> PRT

15<213> Mus musculus

<400> 5

Leu Thr Tyr Thr Asn Asp Phe Ser Asp Asp Ile Val Lys Phe His Cys

1

5

10

15

20Leu Ala Asn Val

20

<210> 6

<211> 20

25<212> PRT

<213> Rattus norvegicus

<400> 6

Leu Thr Tyr Ile Asn His Phe Ser Asp Asp Ile Tyr Asn Leu Asn Cys

30 1

5

10

15

Leu Ala Asn Ile

20

<210> 7

35<211> 20

<212> PRT

<213> Cricetulus griseus

<400> 7

40Phe Thr Tyr Ala Asn Glu Phe Ser Glu Asp Ile Thr Asp Phe Asp Cys

3

1 5 10 15

Leu Ala Asn Val

20

5<210> 8

<211> 20

<212> DNA

<213> Homo sapiens

10<400> 8

atggggcata tcagagccta

20

<210> 9

<211> 20

15<212> DNA

<213> Homo sapiens

<400> 9

gtccaatggg gaagttctct

20

20

<210> 10

<211> 20

<212> DNA

<213> Homo sapiens

25

<400> 10

tcattgtcct gcagaaggta

20

<210> 11

30<211> 20

<212> DNA

<213> Homo sapiens

<400> 11

35cagggctttt ctgagtcgtc

20

<210> 12

<211> 20

<212> DNA

40<213> Homo sapiens

<400> 12
ctgctcggtc aaacgggtat 20

<210> 13
5<211> 20
<212> DNA
<213> Homo sapiens

<400> 13
10cagcaagcac gatattggat 20

<210> 14
<211> 20
<212> DNA
15<213> Homo sapiens

<400> 14
gagttgggag accatgcagt 20

20<210> 15
<211> 20
<212> DNA
<213> Homo sapiens

25<400> 15
ggttcttatt cagcagaaat 20

<210> 16
<211> 20
30<212> DNA
<213> Homo sapiens

<400> 16
ggtggtgtg gagacaaatc 20

35
<210> 17
<211> 20
<212> DNA
<213> Homo sapiens

40

<400> 17
acttggacct ttccagcaac 20

<210> 18
5<211> 19
<212> DNA
<213> Homo sapiens

<400> 18
10ctttatccaa ccaggtgca 19

<210> 19
<211> 23
<212> DNA
15<213> Homo sapiens

<400> 19
tgggagaatt tagaaatgaa gga 23

20<210> 20
<211> 21
<212> DNA
<213> Homo sapiens

25<400> 20
tttcttcatt ttccctggtg a 21

<210> 21
<211> 20
30<212> DNA
<213> Homo sapiens

<400> 21
tggacagttt cccacattga 20

35
<210> 22
<211> 22
<212> DNA
<213> Homo sapiens

40

<400> 22

ttcaaaggtt gctgttctca aa

22

<210> 23

5<211> 23

<212> DNA

<213> Homo sapiens

<400> 23

10tcaaacttct tgggcttaga aca

23

<210> 24

<211> 20

<212> DNA

15<213> Homo sapiens

<400> 24

cagagttgct ttcaatggca

20

20<210> 25

<211> 20

<212> DNA

<213> Homo sapiens

25<400> 25

tccagggaaaa cttccttcca

20

<210> 26

<211> 18

30<212> DNA

<213> Homo sapiens

<400> 26

ttcattggat acgtttcc

18

35

<210> 27

<211> 20

<212> DNA

<213> Homo sapiens

40

<400> 27

accagagttt cctgcaatgg

20

<210> 28

5<211> 20

<212> DNA

<213> Homo sapiens

<400> 28

10tgccctgtgct gagtttgaat

20

<210> 29

<211> 20

<212> DNA

15<213> Homo sapiens

<400> 29

cggtcctcag tgtgcttgta

20

20<210> 30

<211> 20

<212> DNA

<213> Homo sapiens

25<400> 30

ccaggatgag gactgggtaa

20

<210> 31

<211> 20

30<212> DNA

<213> Homo sapiens

<400> 31

aagccgaaaag gtgattgttg

20

35

<210> 32

<211> 23

<212> DNA

<213> Homo sapiens

40

<400> 32

tatcatcttc attgtcctgc aga

23

<210> 33

5<211> 20

<212> DNA

<213> Homo sapiens

<400> 33

10tcattgtcct gcagaaggta

20

<210> 34

<211> 20

<212> DNA

15<213> Homo sapiens

<400> 34

gacgactcag aaaagccctg

20

20<210> 35

<211> 20

<212> DNA

<213> Homo sapiens

25<400> 35

aattggcagg aagcaacatc

20

<210> 36

<211> 21

30<212> DNA

<213> Homo sapiens

<400> 36

agttagtcc tctgaacttt c

21

35

<210> 37

<211> 20

<212> DNA

<213> Homo sapiens

40

<400> 37
cgtgctcagc attctaacct 20

<210> 38
5<211> 20
<212> DNA
<213> Homo sapiens

<400> 38
10gaacacctca ctttgtgcag 20

<210> 39
<211> 21
<212> DNA
15<213> Homo sapiens

<400> 39
cttgatagtc cagaaaaggc t 21

20<210> 40
<211> 20
<212> DNA
<213> Homo sapiens

25<400> 40
ccgcaagtct gtgcaataaa 20

<210> 41
<211> 24
30<212> DNA
<213> Homo sapiens

<400> 41
gtcagcttat gaaggctaat ttct 24
35
<210> 42
<211> 22
<212> DNA
<213> Homo sapiens
40

10

<400> 42

caaattgcac aggccctcta ga

22

<210> 43

5<211> 26

<212> DNA

<213> Homo sapiens

<400> 43

10aaaagtctttt accctttcaa tagtca

26

<210> 44

<211> 23

<212> DNA

15<213> Homo sapiens

<400> 44

agagatttga gtttcaatgt ggg

23

20<210> 45

<211> 20

<212> DNA

<213> Homo sapiens

25<400> 45

ctttaggctg gttgtcccaa

20

<210> 46

<211> 24

30<212> DNA

<213> Homo sapiens

<400> 46

tgaaaactca ctcatttgtt tcaa

24

35

<210> 47

<211> 20

<212> DNA

<213> Homo sapiens

40

11

<400> 47

cttcgagact ggacaaggcca

20

<210> 48

5<211> 20

<212> DNA

<213> Homo sapiens

<400> 48

10gagaggtcca ggaaggtcaa

20

<210> 49

<211> 20

<212> DNA

15<213> Homo sapiens

<400> 49

acctggaggg agttcagaca

20

20<210> 50

<211> 20

<212> DNA

<213> Homo sapiens

25<400> 50

aagagctgcc tctggtcctt

20

<210> 51

<211> 20

30<212> DNA

<213> Homo sapiens

<400> 51

tacaaggcaca ctgaggaccg

20

35

<210> 52

<211> 20

<212> DNA

<213> Homo sapiens

40

12

<400> 52

tttatgcagc cagcaagaag

20

<210> 53

5<211> 20

<212> DNA

<213> Homo sapiens

<400> 53

10ggaggcaccc cttcttctaa

20

<210> 54

<211> 20

<212> DNA

15<213> Homo sapiens

<400> 54

gcggctctgg atgaagtgct

20

20<210> 55

<211> 20

<212> DNA

<213> Homo sapiens

25<400> 55

ctgagcaggg tcttctccac

20

<210> 56

<211> 20

30<212> DNA

<213> Homo sapiens

<400> 56

agatgttgct tcctgc当地

20

35

<210> 57

<211> 20

<212> DNA

<213> Homo sapiens

40

<400> 57

cagggctttt ctgagtcgtc

20

<210> 58

5<211> 20

<212> DNA

<213> Homo sapiens

<400> 58

10tgaacaagtg ttggacccag

20

<210> 59

<211> 21

<212> DNA

15<213> Homo sapiens

<400> 59

gattagcagc cctgcataatc t

21

20<210> 60

<211> 20

<212> DNA

<213> Homo sapiens

25<400> 60

gctcacagaa gcagtgagga

20

<210> 61

<211> 20

30<212> DNA

<213> Homo sapiens

<400> 61

taggctctga tatgccccat

20

35

<210> 62

<211> 10665

<212> DNA

<213> Homo sapiens

<220>
 <221> misc_feature
 <222> (1) ... (10665)
 <223> n = A,T,C or G

5

<400> 62

aaaatactcc	cttgcctcaa	aaactgctcg	gtcaaacggg	gata	gcaaaac	cacgcattca	60
cagggccact	gctgctcaca	aaaccagtga	ggatgatgcc	aggat	gatgt	ctgcctcg	120
cctggctggg	actctgatcc	cagccatggc	cttcctctcc	tgcgtgagac	cagaa	agctg	180
10ggagccctgc	gtggaggtat	gtggctggag	tca	gctc	cctc	tgaactttcc	240
cccagaactt	ctcactgtgt	gccctgg	ttt	tat	ttt	gcaaaaaaaa	300
attaccta	agactcaaga	agccacagag	atcaaataat	tcattgttac	agg	gcactag	360
aggcagccat	tgggggttt	ttccat	ttgg	aaat	ttt	tgctaacagg	420
aacatagatc	tgcttaaggt	ccctgctctg	ctac	ctt	gtg	gctctgtgaa	480
15aacctgtctg	agactagttt	tcgc	atctgt	aag	agaatta	taatac	540
agtaa	gcaga	ctg	ttc	agt	gtc	at	600
gcagtcaccc	tgctc	c	tttc	aat	ctc	agga	660
gaaagaactt	tct	a	ttt	ttt	gag	tgct	720
atgaaaaaaa	taa	gaga	atg	aaa	aggaaa	agagagag	780
20ggaaatatgt	ataatgtc	ag	ttt	ctt	tc	tttagt	840
tggttggtaa	tcttatt	atc	ttt	ttt	ttt	ccctgc	900
ttgctttaga	aacccat	atc	ttt	ttt	ttt	gactt	960
gtcagaaact	caagagagaa	aaagcc	atc	ttt	ttt	atagg	1020
atcaagtaat	at	ttt	ttt	ttt	ttt	ccctcaattc	1080
25cctgcccata	gtc	ctt	c	ttt	ttt	ttt	1140
agata	attt	tct	attt	ttt	ttt	ttt	1200
aatattgtct	ttg	agg	ctcc	atgg	ttt	ttt	1260
gcatgttga	act	ctg	actt	tgc	cat	ttt	1320
atctttaat	gtt	tat	ttt	ttt	ttt	ttt	1380
30cgtatggtaa	ggg	atta	atg	at	at	ttt	1440
atactgttagc	ggg	ctt	ttt	aa	act	ttt	1500
cattctattt	ttt	caa	aca	aa	act	ttt	1560
ttggaggaaa	tg	agg	gtt	ttt	ttt	ttt	1620
aatgtggaa	aag	tag	gtt	ttt	ttt	ttt	1680
35cttatttact	agg	ttt	ccacc	atgg	aaat	ttt	1740
catca	ttt	ctc	agg	gtt	ttt	ttt	1800
catgacta	atg	agg	gtt	ttt	ttt	ttt	1860
attt	at	agg	gtt	ttt	ttt	ttt	1920
gcacatgtgc	ag	agg	gtt	ttt	ttt	ttt	1980
40gcata	gat	at	ttt	ttt	ttt	ttt	2040

catgctcatc ttctctgtat ctttccaatt ttagtatatg tgctactgca gcaagcacga	2100
tattggatat tttattacct acatttaca tatgataaaa tgaggctcac tgaggtttt	2160
cttttgttcg ttttattttg ttttggggaa aaagacttgg ccctaaacca cacagaagag	2220
ctggcatgaa acccagagct ttcagactcc ggagcctcag cccttcaccc cgattccatt	2280
5gcttcgtcttgcg aaatgctgcc gtttatcnc ggaggtaga atgctgagca cgttagtaggt	2340
gctctttact ttctaatcta gagtaagaca atttataagc atgaatttag tgaatggatg	2400
gatggatata tggatgaaag gatggacaga tggatgaaag gttgactgaa ttttgcttgc	2460
gcacaaaaag aggcccctct ccaccatctc tggtaggatgaggggagtt gggagaccat	2520
gcagtaaaga tacttcatgt catgtataat cattgcaggt ggttcctaat attacttata	2580
10aatgcatgga gctgaatttc tacaaaatcc ccgacaacctt ccccttcacc accaagaacc	2640
tggacctgag cttaatccc ctgaggcatt taggcagcta tagttcttc agtttcccg	2700
aactgcaggt gctggattt tccaggtat gaatccactt ttacatactg cacaaggtga	2760
ggtgttcatt gtcctatcat ttcattattt gactggaaag cttgggggttggatctcat	2820
cttcattcac ttattcattt atacaacaga tgtcttatta actatataac cttgagcaag	2880
15ctacccat tctccaggc tcagtttctt aatctgtgaa gtggcagtt ggctgagaca	2940
gcttctaagg gcaattctaa ttttaggttt tcttttaaga caggagagaa aattagctt	3000
aattcttca taagcagcta tttattgact acttgctata tggtagcac tctgcaagaa	3060
gacaggcata tattgatata taacacacag cccctgttgc taaggaggca tatcttcttgc	3120
aaagagttaa taccttaaag tcctgggtat ggtcctgggt acatagtata tagtcaacac	3180
20attttaatta tgatttttg gatctggaaa ctgatataaa gatagcgaca tataacagta	3240
ggtgataaat tatgtttaaa ctaaaggtaa ctaattgtat tttcagaag aggggccttc	3300
tctgtggggat gtagtcaaga aagattcatg aactgcataa gattcaaaca atgtctgaa	3360
tattttttact agtgggtggca ggtgaaatgt catcttgata ttttagggaa accaaattct	3420
aaaagggttt tcatcatcgg gccttattt gcaaattcgaa ctagataatg gatcatgttc	3480
25tctgcaatgg tttgtaaaac atttcaaaac attttacata ttttttattt tagaaattat	3540
tgataaaagac taaggtcaca gtataaaaat cttttttaga gcagacattt ctgtagaaga	3600
gtgaacatat gacctattt actctaattt ggatataagat aggtgtAAC aaaggagtaa	3660
tggaaacaat tcaaaggcag tggtagtgatg catanagtcc tgggggggtc agaagacctg	3720
agcccaagtt taccccaac atttataacc catgtacact tagcatattt cttcatctcc	3780
30cttaatcctt agttcatat ctgatcaatg gaaatgatga aacttattct gctggattaa	3840
atgtgataat aaatattaat atgctgtata tattttaaatt ttataaaaat atattttata	3900
agcataaaagt attcttacag aatttcatta ggtttttaaa ataatttcaa cttttttttt	3960
tgattcaggg atttacatgg ttatattgcg taatgctgag gtgttagggta caatcgatac	4020
catcaactcg gtagtgagca tagtacccaa tagtttagttt ttcaaccctt gctgctttct	4080
35ctctatcccc tctcttagaa tccccagggt ctatttttgt catctttagt tccatgtgtat	4140
ctccatgttt ggatcctact tataaagtga gaactcatgg tatttggctt tctgtncctt	4200
tgttngctaa tttgcttagg ataatggcta ctagctgcat ctatgccatt atgttctaaa	4260
tttcanttnc ctgcatgaaa attttgtcaa gtactctatt aaggttagacc acctctccct	4320
tttttttca aacaagaagt agnntttccc aaacaatgcc ctatggaaat tnatcttcaa	4380
40tccnnngata cccaaataact tgccccaaan cttatctg ncttacagag aggccacctt	4440

ccttcgtaa cccataggag atttggattg gtaagaatgc tttgtatag cccagcagcc	4500
ttcttcccc tataaaaaata tatatatant cttttatag gtgaggaact gaagctgaa	4560
taatttaaat gacttatata catnatcatt gcttgtagc cacagaccag agatthaagt	4620
tcncatctcc agaatccaaac tttaatgttt tctttgtctt aataactctac ttctctaaag	4680
Stgattatcac caatgtaatg atatagagnac acagcaagac ccttccttc tcacctaatg	4740
tatagagcaa tgcatcagata gaatgtatggg ctataacaat catataattg aaagaaaagaa	4800
cttcaaaaat aatcaagttc agctgtttga ttatataatg tgataactaa aacctagaga	4860
ggaaaagagg tactcaagat cacacagtag gagaggactg cagaaacacc aaacccaagc	4920
tctttgtcc actcttccag cgttcttct actataactgc ctatccttta tctagttacc	4980
10aataaataaac aaaagcttgg accacaatgc ttttattgtc taggaaactc ctgaagaagc	5040
taaataaaaat ggggtgggaa tattgtaaat gtaattcagg ctggattaag aaagaactta	5100
tttgacattg taactgacaa gcacctgcaa tgctgaaagg aatttttcat tggcntgctg	5160
tttgctggc tgcataaaag ccctgtctct aggacatgtc tctgaacatt gtgtgttagca	5220
tggcttcat ttcttttagg ataaaaattca aaacccttta tctgggttggg aaacctctgc	5280
15ctaattggga accttccttc tccacaactc catattgtac actccaattt catctctgtt	5340
ctccaaaccat ggaagctatt tgtcatgatt ctccttgc tcatttttt tctgtcaacc	5400
ttggggcttt tgggtttgtct gttcaattca ctcctttta ttgttaactt ctactcatct	5460
ttcaattttc aacttaagtg ttctcagaga aacctacttt gatttcttg gtccanaacg	5520
gttctctgga tggtaactct tatagcacat aattttact ttttccaca aaactcgctc	5580
20ctatcacctg ttacaaggcat ttacctctga taacaagaac ttcaaaatat ctatgttca	5640
tgtaaggact tttcataaac attaagagta tctgtgacac ttatgtgtaa tgtttgcgtat	5700
ctctgaaatt gatatttacc agtcatttt cttggctacc aactaacaac tatccatatt	5760
atctgtacca atcagatgta taatcacaat tttgtgtgac agaaaatggc taaacttgat	5820
ccaaggctat tacatgctt atcaactgca caatcttata atatgtcaat tattgatctt	5880
25taactgattt ctttcattatg gatttctcc tctgcttatac atgtatgcct aacatgacaa	5940
aaaagagcct atcattgcag ccagtatgat aataactcagt ctgtggggct tcttatttgc	6000
ttattccatc atcatctgatc ctgcttgcata tgcacaatca tatgaccat	6060
cacatctgta tgaagagctg gatgactagg attaatattc tatttttaggt tcttattcag	6120
cagaaatatt agataatcaa tggctttta ttccctgttagg tggtaaatcc agacaattga	6180
30agatggggca tatcagagcc taagccacct ctctaccccttta atattgacag gaaaccccatt	6240
ccagagtttta gccctggag cttttctgg actatcaagt ttacagaagc tggggctgt	6300
ggagacaaat ctagcatctc tagagaactt cccatttggc catctaaaaa ctttggaaaga	6360
acttaatgtg gctcacaatc ttatccaatc ttcaaaattt cctgagtatt tttctaatct	6420
gaccaatcta gagcaactgg acctttccag caacaagatt caaagtattt attgcacaga	6480
35cttcgggtt ctacatcaaa tgcccctact caatctctt ttagacctgt ccctgaaccc	6540
tatgaacttt atccaaccat gtgcatttaa agaaatttagg cttcataagc tgactttaag	6600
aaataatttt gatagttaa atgtaatgaa aacttgtatt caaggtctgg ctgggttaga	6660
agtccatcgt ttgggtctgg gagaatttag aaatgaagga aacttggaaa agtttgacaa	6720
atctgctcta gagggcctgt gcaatttgac cattgaagaa ttcccgatta gcatacttag	6780
40actactaccc ctatgtatattt attgacttatt ttaattgggt gacaaatggt tcttcatttt	6840

ccctggtag tttttttt gaaaggtaa aagactttc ttataattt ggttggcaac
attnaattt agttaactgt aaatttggac agtttcccac attgaaactc aaatctctca
aaaggcttac tttcaactcc aacaaaggta ggaatgctt ttcagaagtt gatctacc
gccttgagtt tcttagatctc agtagaaatg gcttgagttt caaagggtgc tggttctcaaaa
SgtgatTTgg gacaaccagc ctaaagtatt tagatctgag cttcaatggt gttattacca
tgagttcaaa cttcttgggc ttagaacaac tagaacatct ggatttccag cattccaatt
tgaaacaaat gagttagttt tcagtattcc tatcactcag aaacctcatt taccttgaca
tttctcatac tcacaccaga gttgcttca atggcatctt caatggctt tccagtc
aagtcttgc aatggctggc aattcttcc aggaaaactt ccttccagat atcttc
10agctgagaaa cttgacccctc ctggacccctc ctcagtgtca actggagcag ttgttccaa
cagcatttaa ctcactctcc agtcttcagg tactaaatat gagccacaac aacttcttt
cattggatac gtttccttat aagtgtctga actccctcca ggttcttgat tacagtctca
atcacataat gacttccaaa aaacaggaac tacagcattt tccaagtagt cttagcttct
taaatcttac tcagaatgac tttgcttgc cttgtgaaca ccagagttt ctgcaatgg
15tcaaggacca gaggcagctc ttgggtggaaag ttgaacgaat ggaatgtgca acaccc
ataagcaggg catgcctgtg ctgagtttga atatcacctg tcagatgaat aagaccatca
ttgggtgttc ggtcctcagt gtgcttgc tatctgttgc agcagttctg gtctataagt
tctatTTca cctgatgtt cttgctggct gcataaaagta tggttagaggt gaaaacatct
atgatgcctt tggttatctac tcaagccagg atgaggactg ggtttagaaat gagcttag
20agaattttaga agaagggggtg cttccatttc agctctgcct tcactacaga gactttattc
ccgggtgtggc cattgctgcc aacatcatcc atgaaggttt ccataaaagc cgaaaggta
ttggtgttgt gtcccagcac ttcatccaga gccgctggtg tatctttgaa tatgagattt
ctcagacctg gcagttctg agcagtcgtg ctggatcat cttcattgtc ctgcagaagg
tggagaagac cctgctcagg cagcaggtgg agctgtaccg cttctc
25acccctggagtg ggaggacagt gtcctggggc ggcacatctt ctggagacga ctcagaaaag
ccctgctgga tggtaaatca tggaaatccag aaggaacagt gggtacagga tgcaattggc
aggaagcaac atctatctga agaggaaaaaa taaaaacccctc ctgaggcatt tcttgc
ctgggtccaa cacttggta gttataatgtt attaaatgtt gccacatgtc aggcctttag
ctaagggtga gtaattccat ggtgcacttag atatgc
30ccagtcaga gggaaataat gctagactaa aatacagagt cttccaggtg ggcatttcaa
ccaactcagt caaggaaccc atgacaaaga aagtcatcc aactcttacc tcatcaagtt
gaataaaagac agagaaaaaca gaaagagaca ttgttcttt cctgagttt ttgaatggaa
attgtattat gttatagcca tcataaaacc attttggtag ttttgcactga actgggtgtt
cacttttcc ttttgattt aatacaattt aaattctact tgatgc
35gggctccatg tgcaagatgc cccttccatt ttaagtctgt ctccttacag aggttaaagt
ctagtggtca attcctaagg aaacctgatt aacacatgct cacaaccatc ctggcattc
tcgagcatgt tctatTTTT aactaatcac ccctgatata ttttatttt tatatatcca
gttttcattt ttttacgtct tgcctataag ctaatatcat aaataaggtt gtttaagacg
tgcttcaat atccatatta accactattt ttcaaggaag tatggaaaag tacactctgt
40cactttgtca ctgcgtgtca ttccaaagtt attgcctact aagtaatgac tgcatgaaa

gcagcattga aataatttgt ttaaaggggg cactcttta aacgggaaga aaattccgc	9300
ttcctggct tatcatggac aattgggct ataggcatga aggaagtggg attacccat	9360
gaagtcacct tttcttgatt ccagaaacat atgggctgat aaaccgggg tgacccatg	9420
aatgagttg cagcagatgt ttatTTTT cagaacaagt gatgtttgat ggacctatga	9480
SatctatTTAG ggagacacag atggctggg tccctcccct gtacccttct cactgccagg	9540
agaactacgt gtgaaggat tcaaggcagg gagtatacat tgctgttcc tggtggcaa	9600
tgctccttga ccacatttg ggaagagtgg atgttatcat tgagaaaaca atgtgtctgg	9660
aattaatggg gttcttataa agaaggtcc cagaaaagaa tgttcattcc agcttcttca	9720
ggaaacacgga acattcaagg aaaaggacaa tcaggatgtc atcaggggaaa tgaaaataaa	9780
10aaccacaatg agatatcacc ttataccagg tagatggcta ctataaaaaa atgaagtgtc	9840
atcaaggata tagagaaatt ggaacccttc ttcactgctg gagggatgg aaaatggtgt	9900
agccgttatg aaaaacagta cggaggttc tcaaaaatta aaaatagaac tgctatatga	9960
tccagcaatc tcacttctgt atatataccc aaaataattg aaatcagaat ttcaagaaaa	10020
tatttacact cccatgttca ttgtggcact cttcacaatc actgtttcca aagttatgga	10080
15aacaacccaa atttccattt gaaaataaaat ggacaaagga aatgtgcata taacgtacaa	10140
tggggatatt attcagccta aaaaaaggggg ggatcctgtt atttatgaca acatgaataa	10200
acccggaggc cattatgcta tgtaaaatga gcaagtaaca gaaagacaaa tactgcctga	10260
tttcatttat atgaggttct aaaatagtca aactcataga agcagagaat agaacagtgg	10320
ttccttaggaa aaaggagggaa gggagaaaatg agggaaatagg gagttgtcta attggatataa	10380
20aatttatagta tgcaagatga attagctcta aagatcagct gtatagcaga gttcgatataa	10440
tgaacaatac tgtatttatgc acttaacatt ttgttaagag ggtacctctc atgttaagtg	10500
ttcttaccat atacatatac acaaggaagc ttttgaggt gatggatata tttattacct	10560
tgattgttgt gatggtttga caggtatgtc actatgtcta aactcatcaa attgtataca	10620
ttaaatatat gcagttttat aatatcaaaa aaaaaaaaaa aaaaa	10665

25

<210> 63
<211> 28
30<212> DNA
<213> Homo sapiens

<400> 63
atTTTGTttt gTTTTAAAG ACTTGGCC

28

35
<210> 64
<211> 28
<212> DNA
<213> Homo sapiens

40

<400> 64

gtcatgtgta atcattgcag gtggttcc

28

<210> 65

5<211> 28

<212> DNA

<213> Homo sapiens

<400> 65

10atgtctttt attcctgttag gtgtgaaa

28

<210> 66

<211> 30

<212> DNA

15<213> Artificial Sequence

<220>

<223> A primer

20<400> 66

gattagcata cttagactac tacctccatg

30

<210> 67

<211> 27

25<212> DNA

<213> Homo sapiens

<400> 67

gatcaacttc tgaaaaagca ttccccac

27

30

<210> 68

<211> 31

<212> DNA

<213> Artificial Sequence

35

<220>

<223> A primer

<400> 68

40gggttgctgtt ctcaaagtga ttttgggaga a

31

<210> 69
<211> 30
<212> DNA
<213> Homo sapiens
5
<400> 69
acctgaagac tggagagtga gttaaatgct 30

<210> 70
10<211> 1360
<212> DNA
<213> Homo sapiens

<220>
15<221> misc_feature
<222> (1)...(1360)
<223> n = A,T,C or G

<400> 70
20ttccacttct aagagctgcc tagagtagtc aagattatag agacaaaagt agtgcata 60
ttcaaggccc tagggaaagg ggaaatgggg agttatttat taatgaatag tggtgatgat 120
tgtacaaaaa tatgaacata attaatgcc ctaaattgtt cacatacaaa tggtcaagat 180
aataaatttt atgttatgtc atgttatgtt atgtgatttt accataatac agaaaatgaa 240
aaaagaaaaag aaagaaagta aagcttagcg gttncatga ctgnccaat gcctcaaagc 300
25catgagtcga cccagctgag atctganctt cagtatattc cattctgaaa tcccagactt 360
ttcccaatct tcttgtactt ttcaaactgt gttcagttg aggtttattt tcagtttgt 420
atgtgagttt ctgcgaaga agggcgggcc aaattgtgtc ctgcaaaaac ctacatatcg 480
aagtccctaac ccctctacct cagactatga ctgtatatgg agagagagcc ttgaaagagg 540
tatgtaaaggta agaatgaggt cattatggtg ggcctaatac caacataact ggtgcctta 600
30taagaagggg agattagaat tcagacacac ttgctgacac cttgagttca gactggaagc 660
ctctagaatt gtgagaaaaat gaatgtctgt tgtttaagcc acccagtctg tggtatttcc 720
ttatggcagc cccagcaaac taatacaaat agtgtttcca cagctgaaac aaaattggaa 780
aatcaccgtc atcctagaga gttacaaggg ctattttaat agaacctgtat tgtttccta 840
aattcaccaa gcccaggcag aggtcagatg actaattggg ataaaagcca actagttcc 900
35tcttgctgtt tcttttagcca ctggctgcga ggcgtttct tcttctaact tccctccctg 960
tgacaaaaaga gataactatt agagaaacaa aagtccagaa tgctaaagggtt gcccgtttca 1020
cttcctctca cccttagcc cagaactgct ttgaatacac caattgctgt ggggcggctc 1080
gaggaagaga agacaccagt gcctcagaaa ctgctcggtc agacgggtat agcgagccac 1140
gcattcacag ggccactgct gtcacagaa gcagtgagga tggatgccagg atgatgtctg 1200
40cctcgcgccct ggctggact ctgatccccag ccatggccctt cctctccctgc gtgagaccag 1260

aaagctggga gccctgcgtg gaggtatgtg gctggagtca gtcctctga acttccctc	1320
acttctgccc agaacttctc actgtgtgcc ctggttgtt	1360

<210> 71

5<211> 1333

<212> DNA

<213> Homo sapiens

<400> 71

10cgcatcatgg atttgtgtgt catcctgtg cagggccat gctcatcttc tctgtatcct	60
tccaaattta gtatatgtgc tactgcagca agcacgatat tggatattt attacctaca	120
ttttacatat gataaaatga ggctcaactga ggttttctt ttgttcgttt tattttgttt	180
tgttttaaa gacttggccc taaaccacac agaagagctg gcatgaaacc cagagcttc	240
agactccgga gcctcagccc ttccacccga ttccattgtct tcttgctaaa tgctccgtt	300
15tttatcacgga gtttagaatg ctgagcacgt agtaggtgct cttaactttc taatctagag	360
taagacaatt tataaggcatg aattgagtga atggatggat ggatataatgg atggaaggat	420
ggacagatgg atgaaagggtt gactgaattt tggcttgca caaaaagagg cccctctcca	480
ccatctctgg tctaggagag gggagttggg agaccatgca gtaaagatac ttcatgtcat	540
gtgtaatcat tgcaggtggt tcctaataatt acttataaat gcatggagct gaatttctac	600
20aaaatccccg acaacctccc cttctcaacc aagaacctgg acctgagctt taatcccctg	660
aggcatttag gcagctatacg cttcttcagt ttcccagaac tgcaggtgct ggatttatcc	720
aggtaatgaa tccactttt catactgcac aaggtgaggt gttcattgtc ctatcatttc	780
attattggac tggaaagctt ggtttgtgga gtctcatctt cattcaactt ttcattcata	840
caacagatgt cttattaact atataacatt gagcaagcta cctctattct ccaggtctca	900
25gttttctaattt ctgtgaagta ggcagttggc tgagacagct tctaaggca attctaattt	960
tagttttct tttaagacag gagagaaaat tagcttaaat tctttcataa gcagctattt	1020
attgactact tgctatatgt tgcactct gcaagaagac aggcatatat tgatataaa	1080
cacacagccc ctgttggtaa ggaggcatat cttcttgaaa gagttaaatac cttaaagtcc	1140
tgggtatggc cttgggtaca tagtataatg tcaacacatt ttaattatga tttttggat	1200
30ctggaaaactg atataaaagat agcgacatata aacagtaggt gataaaattat gttaaacta	1260
aaggttaacta attgtatttt tcagaagagg ggccttctct gtggtggta gtcaagaaag	1320
attcatgaac tgc	1333

<210> 72

35<211> 6786

<212> DNA

<213> Homo sapiens

<220>

40<221> misc_feature

<222> (1)...(6786)

<223> n = A,T,C or G


<400> 72

5ggtaagaatg	ctttgtata	gcccagcagc	cttcttccc	ctatagaaat	atatatatan	60
tcttttata	ggtgaggaac	tgaagcttga	ataattaaa	tgacttatat	acatnatcat	120
tgcttgttag	ccacagacca	gagatttaag	ttcnatctc	cagaatccaa	cttaaatgtt	180
ttcttgtct	taatactcta	cttctctaaa	gtgattatca	ccaatgtaat	gatatagagn	240
cacagcaaga	cccttcctt	ctcaccta	gtatagagca	atgcagagat	agaatgatgg	300
10gctataaca	tcatataatt	gaaagaaaaga	acttcaaaaa	taatcaagtt	cagctgtttg	360
atttataat	gtgataacta	aaacctagag	aggaaaagag	gtactcaaga	tcacacagta	420
ggagaggact	gcagaaaacac	caaaccacaa	ctctttgtc	cactcttcca	gcgttcttc	480
tactatactg	cctatcctt	atctagttac	caataaataa	caaaagctt	gaccacaatg	540
cttttattgt	ctaggaaact	cctgaagaag	ctaaataaaa	tgggtgggga	atattgtaaa	600
15gttaattcag	gctggattaa	gaaagaactt	atttgacatt	gtaactgaca	agcacctgca	660
atgctgaaag	gaattttca	ttggcntgct	gtttgctggg	ctgcatcaaa	gccctgtctc	720
taggacatgt	ctctgaacat	tgtgtgtagc	atggcttca	tttcttttag	gataaaaattc	780
aaaaccctt	atctggttgg	taaacctctg	cctaattggg	aaccttctt	ctccacaact	840
ccatattgt	cactccaatt	tcatctctgt	tctccaacca	tggagctat	ttgtcatgat	900
20tcctcctgt	gtcattttt	ttctgtcaac	cttggggctt	'ttgtgtttgc	tgttcaactc	960
acccctttt	attgttaact	tctactcatc	tttcaatttt	caacttaagt	gttctcagag	1020
aaacctactt	tgattttctt	ggtccanaac	ggttctctgg	atgtgaactc	ttatagcaca	1080
taattttcac	tttttccac	aaaactcgct	cctatcacct	gttacaagca	tttacctctg	1140
ataacaagaa	ctttcaaata	tctagctgtc	atgtaa	gacac	tttcataaaa	1200
25atctgtgaca	cttatgtgta	atgtttcgta	tctctgaaat	tgatatttac	cagtcattta	1260
tcttggtac	caactaaca	ctatccat	tatctgtacc	aatcagatgt	ataatcacaa	1320
ttttgtgtga	cagaaaatgg	ctaaacttga	tccaaggcta	ttacatgctt	tatcaactgc	1380
acaatcttta	tatatgtcaa	ttattgatct	ttanctgatt	tccttctt	ggattttctc	1440
ctctgctt	catgtatgcc	taacatgaca	aaaaagagcc	tatcattgca	gccagtatga	1500
30taataactcag	tctgtggggc	,ttcttatttg	cttattccat	catcatctgt	cctgcttgat	1560
gtctttgcct	atgcacaatc	atatgaccca	tcacatctgt	atgaagagct	ggatgactag	1620
gattaatatt	ctatTTtagg	ttcttattca	gcagaaatat	tagataatca	atgtctttt	1680
attcctgttag	gtgtgaaatc	cagacaattt	aagatggggc	atatcagagc	ctaagccacc	1740
tctctacctt	aatattgaca	ggaaacccca	tccagagttt	agccctggg	gcctttctg	1800
35gactatcaag	tttacagaag	ctggggctg	tggagacaaa	tctagcatct	ctagagaact	1860
tccccattgg	acatctaaa	actttgaaag	aacttaatgt	ggctcacaat	cttatccaat	1920
ctttcaaatt	acctgagttat	ttttctaattc	tgaccaatct	agagcacttg	gaccttcca	1980
gcaacaagat	tcaaagtatt	tattgcacag	acttgcgggt	tctacatcaa	atgcccctac	2040
tcaatctctc	tttagacctg	tccctgaacc	ctatgaactt	tatccaacca	ggtgcattta	2100
40aagaaattag	gcttcataag	ctgactttaa	gaaataattt	tgatagttt	aatgtatga	2160

aaacttgtat tcaaggctcg gctggtttag aagtccatcg tttggttctg ggagaattta	2220
gaaatgaagg aaacctggaa aagttgaca aatctgcctc agagggcctg tgcaatttga	2280
ccattgaaga attccgatta gcatacttag actactaccc cgatgatatt attgacttat	2340
ttaattgtt gacaaatgtt tcttcatttt ccctggtag tgcgtactatt gaaaggtaa	2400
Saagactttc ttataatttc ggatggcaac atttagaatt agttaactgt aaatttggac	2460
agtttcccac attgaaaactc aaatctctca aaaggcttac tttcacttcc aacaaaggta	2520
ggaatgcctt ttcagaagtt gatctaccaa gccttgagtt tctagatctc agtagaaatg	2580
gcttgagttt caaagggtgc tttctcaaa gtgattttgg gacaaccagc ctaaagtatt	2640
tagatctgag ctcaaatggt gttattacca tgagttcaaa cttcttggc tttagaacaac	2700
10tagaacatct ggatttccag cattccaatt tgaacaaat gagtgagttt tcagtattcc	2760
tatcactcag aaacctcatt taccttgaca tttctcatac tcacaccaga gttgcttca	2820
atggcatctt caatggcttg tccagtcgt aagtcttggaa aatggctggc aattcttcc	2880
aggaaaactt cttccagat atttcacag agctgagaaa cttgaccttc ctggacctct	2940
ctcagtgtca actggagcag ttgtctccaa cagcattaa ctcactctcc agtcttcagg	3000
15actaaatat gagccacaac aactctttt cattggatac gttccttat aagtgtctga	3060
actccctcca ggttcttgat tacagtctca atcacataat gacttccaaa aaacaggaac	3120
tacagcattt tccaagtagt cttagttct taaatcttac tcagaatgac tttgcttgta	3180
cttgcataaca ccagagttc ctgcaatggc tcaaggacca gaggcagctc ttgggtggaa	3240
ttgaacgaat ggaatgtgca acacccatcg ataagcaggg catgcctgtg ctgagtttga	3300
20atatatcacctg tcagatgaat aagaccatca ttgggtgtgc ggtcctcagt gtgctttag	3360
tatctgtgt agcagttctg gtctataagt tctatccat cctgatgctt cttgctggct	3420
gcataaaagta tggtagaggt gaaaacatct atgatgcctt tggtatctac tcaagccagg	3480
atgaggactg ggtaaaggaaat gagctgttac agaattttaga agaagggggtg cctccatttc	3540
agctctgcct tcactacaga gactttattc ccgggtgtggc cattgctgcc aacatcatcc	3600
25atgaaggttt ccataaaagc cgaaagggtga ttgttgggt gtcccagcac ttcatccaga	3660
ggcgcgtggc tatctttgaa tatgagattt ctcagacctg gcagtttctg agcagtcgt	3720
ctggtatcat cttcattgtc ctgcagaagg tggagaagac cctgctcagg cagcaggtgg	3780
agctgtaccg ctttctcagc aggaacactt acctggagtg ggaggacagt gtcctggggc	3840
ggcacatctt ctggagacga ctcagaaaag ccctgctggc tggtaaatca tggaaatccag	3900
30aaggaacagt gggtacagga tgcaattggc aggaagcaac atctatctga agaggaaaaaa	3960
taaaaacctc ctgaggcatt tcttgccttgc ctgggtccaa cacttgcatttca gttataatgt	4020
attaaatgct gccacatgtc aggccattatg ctaagggtga gtaattccat ggtgcactag	4080
atatgcaggg ctgctaatttca caaggagctt ccagtgcaga gggataaaat gctagactaa	4140
aatacagagt ctccagggtg ggcatttcaa ccaactcagt caagggaccc atgacaaaga	4200
35aagtcatcc aactcttacc tcatcaagtt gaataaaagac agagaaaaca gaaagagaca	4260
ttgttctttt cctgagtctt ttgaatggaa attgtattat gttatagcca tcataaaacc	4320
attttggtag ttttgactga actgggtgtt cacttttcc tttttgattt aatacaattt	4380
aaattctact tgcgtactgc agtcgtcaag gggctcctga tgcaagatgc cccttcatt	4440
ttaagtctgt ctccatccatcg aggtttaaagt ctagtggctt attccatagg aaacctgtt	4500
40aacacatgct cacaaccatc ctggcatttgc tcgagcatgt tctatccatccatcg aactaatc	4560

ccctgatata ttttatttt tatatatcca gtttcattt tttacgtct tgcctataag 4620
ctaatatcat aaataagggtt gtttaagacg tgcttcaaattt atccatatta accactattt 4680
ttcaaggaag tatggaaaag tacactctgt cactttgtca ctgcgttca ttccaaagtt 4740
attgcctact aagtaatgac tgtcatgaaa gcagcattga aataatttg ttaaagggggg 4800
5cactcttta aacgggaaga aaatttccgc ttcctggct tatcatggac aatttgggct 4860
agaggcagga aggaagtggg atgacctcag gaggtcacct tttcttgatt ccagaaaacat 4920
atgggctgat aaaccgggg tgacctcatg aaatgagttt cagcagaagt ttatttttt 4980
cagaacaagt gatgtttgat ggacctctga atctcttag ggagacacag atggctggga 5040
tccctccccct gtacccttct cactgccagg agaactacgt gtgaaggat tcaaggcagg 5100
10gagtatacat tgctgttcc tggggcaaa tgctccttga ccacattttt ggaagagtgg 5160
atgttatcat tgagaaaaca atgtgtctgg aattaatggg gttttataaa agaaggttcc 5220
cagaaaagaa tgttcatcca gcctcctcag aaacagaaca ttcaagaaaa ggacaatcag 5280
gatgtcatca gggaaatgaa aataaaaacc acaatgagat atcaccttat accaggtaga 5340
atggctacta taaaaaaatg aagtgtcatc aaggatataag agaaatttggg acccttcttc 5400
15actgctggag ggaatggaaa atggtagc cgttatgaaa aacagtacgg aggttctca 5460
aaaattaaaa atagaactgc tataatgatcc agcaatctca cttctgtata tataccaaaa 5520
ataattgaaa tcagaatttc aagaaaatattt ttacactccc atgttcattt tggcactctt 5580
cacaatcact gttccaaag ttatggaaac aacccaaattt tccattgaaa aataaatggg 5640
caaagaaaat gtgcataatac gtacaatggg atattattca gcctaaaaaaa aggggnatc 5700
20ctgttattta tgacaacatg aataaaccccg gagccattat gctatgtaaa atgagcaagt 5760
aacagaaaaga caaatactgc ctgatttcat ttatatgagg ttctaaaata gtcaaactca 5820
tagaagcaga gaatagaaca gtggttccta gggaaaagga ggaagggaga aatgaggaaa 5880
tagggagttg tctaatttgtt ataaaattat agtgcataatg atgaatttagc tctaaagatc 5940
agctgtatag cagagttcgt ataatgaaca atactgtattt atgcacttaa cattttgtta 6000
25agagggtacc tctcatgtt agtgttctta ccatatacat atacacaagg aagctttgg 6060
aggtgatgga tatattttt accttgattt tggtgatggg ttgacaggta tgtgactatg 6120
tctaaactca tcaaatttgta tacattaaat atatgcattt ttataatatc aattatgtct 6180
gaatgaagct ataaaaaaaga aaagacaaca aaattcagtt gtcaaaaactg gaaatatgac 6240
cacagtcaga agtgtttgtt actgagtttgc tcagagtgtg tttgggttga gcaggtctag 6300
30ggtgattgaa catccctggg tgggtttcca tgggtcatgt acttagtgaaa gtagatgtgt 6360
gcatttgc acatatccct atgtatccct atcagggtctg tgggttattt aaagtgtgt 6420
tgtccgcattt atcatatctg tatagaagag agtgcattt tatttcttga agaataatc 6480
catttgcattt ggatgtctat ggctgttga gatgagttctt ctactcttgc gcttgcacag 6540
tagtctcccc ttatccctta tgcttgggg atacgttctt agaccccaag tggatctctg 6600
35agaccgcaga tggtagccaaa cctcatatata gcaatattttt ttcctatataa taaataatc 6660
agataaaagttt catcttctga attaggcaca gtaagagattt aacaataactt aacaataaaaa 6720
ttgaatagttt ataataatata attgtatgtt aagttatgtt aatgtgatctt ctttcttttc 6780
tctctc

1/18



1
FIG.

2/18




FIG. 2A




FIG. 2B




FIG. 2C

3/18




FIG. 3A

4/18




FIG. 3B

5/18

↓

Human (aa 290)	...	LAY	L	D	Y	Y	L	D	D	I	I	D	L	F	N	C	L	T	N	V	...		
Mouse (aa 289)	...	L	T	Y	T	N	D	F	S	D	D	I	V	K	-	F	H	C	L	A	N	V	...
Rat (aa 289)	...	L	T	Y	I	N	H	F	S	D	D	I	Y	N	-	L	N	C	L	A	N	I	...
Hamster (aa 289)	...	F	T	Y	A	N	E	F	S	E	D	I	T	D	-	F	D	C	L	A	N	V	...

FIG. 4

6/18




FIG. 5

7/18




FIG. 6A

8/18




FIG. 6B

9/18




FIG. 6C

10/18




FIG. 6D

11/18

Amino Acid	Codon
Phe	UUU, UUC
Ser	UCU, UCC, UCA, UCG, AGU, AGC
Tyr	UAU, UAC
Cys	UGU, UGC
Leu	UUA, UUG, CUU, CUC, CUA, CUG
Trp	UGG
Pro	CCU, CCC, CCA, CCG
His	CAU, CAC
Arg	CGU, CGC, CGA, CGG, AGA, AGG
Gln	CAA, CAG
Ile	AUU, AUC, AUA
Thr	ACU, ACC, ACA, ACG
Asn	AAU, AAC
Lys	AAA, AAG
Met	AUG
Val	GUU, GUC, GUA, GUG
Ala	GCU, GCC, GCA, GCG
Asp	GAU, GAC
Gly	GGU, GGC, GGA, GGG
Glu	GAA, GAG

FIG. 7

12/18

Original Residue	Exemplary Substitutions	Preferred Substitutions
Ala (A)	val; leu; ile	val
Arg (R)	lys; gln; asn	lys
Asn (N)	gln; his; lys; arg	gln
Asp (D)	glu	glu
Cys (C)	ser	ser
Gln (Q)	asn	asn
Glu (E)	asp	asp
Gly (G)	pro	pro
His (H)	asn; gln; lys; arg	arg
Ile (I)	leu; val; met; ala; phe norleucine	leu
Leu (L)	norleucine; ile; val; met; ala; phe	ile
Lys (K)	arg; gln; asn	arg
Met (M)	leu; phe; ile	leu
Phe (F)	leu; val; ile; ala	leu
Pro (P)	gly	gly
Ser (S)	thr	thr
Thr (T)	ser	ser
Trp (W)	tyr	tyr
Tyr (Y)	trp; phe; thr; ser	phe
Val (V)	ile; leu; met; phe; ala; norleucine	leu

FIG. 8

13/18

HUMAN TLR4 GENOMIC SEQUENCE

AAAATACTCC CTTGCCCTCAA AAACTGCTCG GTCAAAACGGT
GATAGCAAAC CACGCATTCA CAGGGCCACT GCTGCTCACA
AAACCAGTGA GGATGATGCC AGGATGATGT CTGCCTCGCG
CCTGGCTGGG ACTCTGATCC CAGCCATGGC CTTCCCTCTCC
TGCCTGAGAC CAGAAAGCTG GGAGCCCTGC GTGGAGGTAT
GTGGCTGGAG TCAGCTCCTC TGAACTTTCC CTCACTTCTG
CCCAGAACTT CTCACTGTGT GCCCTGGTTT GTTTATTTT
GCAAAAAAAA AAAGAGTTAA ATTACCTTAA AGACTCAAGA
AGCCACAGAG ATCAAATAAT TCATTGTTAC AGGGCACTAG
AGGCAGCCAT TGGGGGTTTG TTCCATTGAG AAATTTGAG
TGCTAACAGG GGCATGAGAT AACATAGATC TGCTTAAGGT
CCCTGCTCTG CTACCTTGTG GCTCTGTGAA GAAATTATCA
AACCTGTCTG AGACTAGTT TCGCATCTGT AAGAGAATTA
TAATACCTTC TTCACTAGAG AGTAAGCAGA CTGCTTCAGT
GTCATTTCTT CCCACTGGTG GTCTTACAC TCAGCTCAA
GCAGTCACCC TGCTCCTTTC AATCTCAGGA AAAAGATGGC
TTTGTGTGTG TGTCTCT:A: G:AGAAAAGAA CTTTCTAAGT
TGGTGCAGA CTTCTGTATG CAGTAATATA GTTTAGTCCA
GAGGATGAAA AAAATAAGAG A:ATGAAAAA GGAAAAGAGA
GAGAGAGA:G AAGAAAAAAG CAAGAGGGAA AT:ATGTATA
ATGTCAGCTA ATGCAAC:AG TTTCTTCTT AGTGAATAC
CAATCAGCTG :GTTG:GTAA TCTT:ATTCA TGATGGATCT
CTTTGTTTT TCCCCTGCGC AGACTTC:AC AGTTGCTTTA
GAAACCCATA GTAGAGCCGA A:CAGCTAAG AAAATGATT
ACAGTGAGGC AGGGTCAGAA ACTCAAGAGA GAAAAAGCCA
GCTGCAGTC : CTGAAGT:TG AGGATATAGG :AGAAAATCA
AGTAATATTG AGCAAAGACT AATTCTTAT CTTGAAGCCA
TCCCTCCCT CAATTCCCTG CCCATAGTCC TCCTCCTTGT
CCTCTTCTCT GNA:TCCCTC TGCTGTTAGG TTA:ATGG:A
GATAGATTTT CTAATTANGC TCACTGCGAG ATAAAACCCA
GCCCATGTTT CTATTAGNCA ATATTGTCTT TGAGGCTCCA
TGGCTTGCAN CATTAAAGCA GACATACGAA TGAAGATCTG
CATGTTGAA CTCTGACTTT GCGCATATTA CTTCATTTCT
TTGAATTTC C ATTTCCTCA TCTTTAAATG CTTATTGAA
GATTAAGTGA AAGTATATAA CAAACAAAGAA CTATGCAGGC
GTATGGTAAG GGATTAATGA TAGATGATAA TAATTAATGT
TGACATCTAT TGATCACTTA TACTGTAGCG GGCTTTAAA
TAAACTCTT AAACACCTTA TCTCATTAA TCCTTCAAAC
ATTCTATTGG TTTCAAACAA CAGAAAACTA CAATTAGCTG
GCTTCTGCAA GGAATTTCGT TGGAGGAAAT GAGAGCATT
AGAAAATTAGA TGGGAGCGTT AGAGAATTAG GCTTACAAAG
AATGTGGGAA AGTAGGCTAG AAAGCAGTGT AAAAACAAAG
ACAGCATAAA GCACTTGACC TTATTTACTA GGTTCCACCA
TGGGAATCCA TGCACCTCAA AGATTTCCCC CTATTTCTAC
ATCACCTTGC TCAAGGGTCA ATGAGCCAAG GAAAAGAATG

FIG. 9

14/18

CAGTTGTCAA AATCTGGGCC ATGACTAAGG AAGGTCTGGA
 CATCTTCACT GCCAGACAGT CTCCCCAATG ATATGGAGTA
 TTTAGAACATGA TACTGGATAT TTTATTATT TTTGTATT
 TCAACTTTA AGTCAGAGG CACATGTGCA GAGCATGCAG
 GTTTATTACA TAAGTAAATG TGTGCCATGG TGATTTGCTG
 CATAGATCAT GAAAATATGG AACGCATCAT GGATTTGTGT
 GTCATCCTTG TGCAGGGGCC ATGCTCATCT TCTCTGTATC
 CTTCCAATT TAGTATATGT GCTACTGCAG CAAGCACGAT
 ATTGGATATT TTATTACCTA CATTTCACAT ATGATAAAAT
 GAGGCTCACT GAGGTTTTTC TTTTGTTCGT TTTATTTGT
 TTTGTTTTA AAGACTTGCG CCTAAACCAC ACAGAAGAGC
 TGGCATGAAA CCCAGAGCTT TCAGACTCCG GAGCCTCAGC
 CCTTCACCCC GATTCCATTG CTTCTTGCTA AATGCTGCCG
 TTTTATCNCG GAGGTTAGAA TGCTGAGCAC GTAGTAGGTG
 CTCTTACTT TCTAATCTAG AGTAAGACAA TTTATAAGCA
 TGAATTGAGT GAATGGATGG ATGGATATAT GGATGGAAGG
 ATGGACAGAT GGATGAAAGG TTGACTGAAT TTTGTGCTTG
 CACAAAAAGA GGCCCCCTCTC CACCATCTCT GGTCTAGGAG
 AGGGGAGTTG GGAGACCATG CAGTAAAGAT ACTTCATGTC
 ATGTGTAATC ATTGCAGGTG GTTCCTAATA TTACTTATCA
 ATGCATGGAG CTGAATTCT ACAAAATCCC CGACAACCTC
 CCCTTCTCAA CCAAGAACCT GGACCTGAGC TTTAATCCCC
 TGAGGCATT AGGCAGCTAT AGCTTCTTCA GTTTCCCAGA
 ACTGCAGGTG CTGGATTAT CCAGGTAATG AATCCACTT
 TACATACTGC ACAAGGTGAG GTGTTCATG TCCTATCATT
 TCATTATTGG ACTGGAAAGC TTGGTTGTG GAGTCTCATC
 TTCATTCACT TATTCAATTCA TACAACAGAT GTCTTATTAA
 CTATATAACC TTGAGCAAGC TACCTCTATT CTCCAGGTCT
 CAGTTTCTA ATCTGTGAAG TAGGCAGTTG GCTGAGACAG
 CTTCTAAGGG CAATTCTAAT TTTAGGTTT CTTTTAAGAC
 AGGAGAGAAA ATTAGCTAA ATTCTTCAT AAGCAGCTAT
 TTATTGACTA CTTGCTATAT GTTGTACACT CTGCAAGAAG
 ACAGGCATAT ATTGATATAT AACACACAGC CCCTGTTGTT
 AAGGAGGCAT ATCTTCTTGA AAGAGTTAAT ACCTTAAAGT
 CCTGGGTATG GTCCTGGTA CATAGTATAT AGTCAACACA
 TTTTAATTAT GATTTTTGG ATCTGGAAAC TGATATAAAG
 ATAGCGACAT ATAACAGTAG GTGATAAATT ATGTTAAAC
 TAAAGGTAAC TAATTGTATT TTTCAGAAGA GGGGCCTTCT
 CTGTGGTGGG TAGTCAAGAA AGATTCAATGA ACTGCATAAG
 ATTCAAACAA TGTCTAGAAT ATTAAAACCA GTGGTGGCAG
 GTGAAATGTC ATCTTGATAT TTTAGGGAA CCAAATTCTA
 AAAGGGTTT CATCATCGGG GCCTTATTG CAAATCGAAC
 TAGATAATGG ATCATGTTCT CTGCAATGGT TTGTAAAACA
 TTTCAAAACA TTTTACATAT TTTTATTAT AGAAATTATT
 GATAAAAGACT AAGGTACACAG TATAAAAATC CTTTTAGAG
 CAGACATTTC TGTAGAAGAG TGAACATATG ACCTATTATA
 CTCTAATTG GATATAGATA GGATGTAACA AAGGAGTAAT

FIG. 9 (Continued)

15/18

GGGAAACAATT CAAAGGCAGT GGTATAGTGC ATANAGTCCT
 GTTGGGGTCA GAAGACCTGA GCCCAAGTTT ACCCCCCAAC
 TTTATAACCC ATGTAACCTT AGCATATTAC TTCATCTCCC
 TTAATCCTTA GTTTCATATC TGATCAATGG AAATGATGAA
 ACTTATTCTG CTGGATTAAA TGTGATAATA AATATTAATA
 TGCTGTATAT ATTTAAATTT TTATAAAATA TATTTTATAA
 GCATAAAAGTA TTCTTACAGA ATTTCATTAG GTTTTAAAAA
 TAATTTCAAC TTTTATTTT GATTCAAGGG AATCGATGGT
 TATATTGCGT AATGCTGAGG TGTAGGGTAC AATCGATACC
 ATCACTCAGG TAGTGAGCAT AGTACCCAAT AGTTAGTTT
 TCAACCCCTG CTGCTTCTC TCTATCCCT CTCTAGTAAT
 CCCCAGGGTC TATTTTGTC ATCTTATGT CCATGTGTAC
 TCCATGTTG GATCCTACTT ATAAAGTGAG AACTCATGGT
 ATTTGGCTTT CTGTCCTTT GTTNGCTAAT TTGCTTAGGA
 TAATGGCTAC TAGCTGCATC TATGCCATTA TGTCTAAAT
 TTCANTTNCC TGCATGAAAA TTTTGTCAAG TACTCTATT
 AGGTAGACCA CCTCTCCCTT TTTTTTCAA ACAAGAAGTA
 GNNTTCCCA ACAATGCCC TTATGGAATT NATCTTCAT
 CCNNGGATAC CCAATAACTT GCCCCAAANC CTTAATCTGN
 CTTACAGAGA GGCCACCTTC CTTCTGTAAC CCATAGGAGA
 TTTGGATTGG TAAGAATGCT TTGTGATAGC CCAGCAGCCT
 TCTTCCCCT ATAGAAATAT ATATATANTC TTTTTATAGG
 TGAGGAAC TG AAGCTGAAT AATTTAAATG ACTTATATAC
 ATNATCATTG CTTGTTAGCC ACAGACCAGA GATTAAAGTT
 CNCATCTCCA GAATCCAAC TAAATGTTT CTTGTCTTA
 ATACTCTACT TCTCTAAAGT GATTATCACC AATGTAATGA
 TATAGAGNCA CAGCAAGACC CTTTCCTTCT CACCTAATGT
 ATAGAGCAAT GCAGAGATAG AATGATGGC TATAACAATC
 ATATAATTGA AAGAAAGAAC TTCAAAAATA ATCAAGTTCA
 GCTGTTGAT TTATAAATGT GATAACTAAA ACCTAGAGAG
 GAAAAGAGGT ACTCAAGATC ACACAGTAGG AGAGGACTGC
 AGAAACACCA AACCCAAAGCT CTTTGTCCA CTCTTCCAGC
 GTTCTTCTA CTATACTGCC TATCCTTAT CTAGTTACCA
 ATAAATAACA AAAGCTTGGA CCACAATGCT TTTATTGTCT
 AGGAAACTCC TGAAGAACG AAATAAAATG GGTGGGAAT
 ATTGTAAATG TAATTCAAGGC TGGATTAAGA AAGAACTTAT
 TTGACATTGT AACTGACAAG CACCTGCAAT GCTGAAAGGA
 ATTTTCATT GGCNTGCTGT TTGCTGGCT GCATCAAAGC
 CCTGTCTCTA GGACATGTCT CTGAACATTG TGTGTAGCAT
 GGCTTCATT TCTTTAGGA TAAAATTCAA AACCCCTTAT
 CTGGTTGGTA AACCTCTGCC TAATTGGAA CCTTCTTCT
 CCACAACCTCC ATATTGTACA CTCCAATTTC ATCTCTGTT
 TCCAACCATG GAAGCTATT GTCATGATTC CTCCTTGCTG
 CATTTTTTT CTGTCAACCT TGGGGCTTT GTGTTGCTG
 TTCACTTCAC CTCCTTTAT TGTTAACCTC TACTCATCTT
 TCAATTTCAC ACTTAAGTGT TCTCAGAGAA ACCTACTTTG
 ATTTCTTGG TCCANAACGG TTCTCTGGAT GTGAACTCTT

FIG. 9 (Continued)

16/18

ATAGCACATA ATTTCACTT TTTCCACAA AACTCGCTCC
 TATCACCTGT TACAAGCATT TACCTCTGAT AACAAAGAACT
 TTCAAAATATC TAGCTGTCAT GTAAGCACTT TTCATAAACCA
 TTAAGAGTAT CTGTGACACT TATGTGTAAT GTTTCGTATC
 TCTGAAATTG ATATTACCA GTCATTTATC TTGGCTACCA
 ACTAACAACT ATCCATATTA TCTGTACCAA TCAGATGTAT
 AATCACAATT TTGTGTGACA GAAAATGGCT AAACATTGATC
 CAAGGCTATT ACATGCTT: ATCAAACGTCA CAATCTTAT
 ATATGTCAAT TATTGATCTT TAACTGATTT CCTTCTTATG
 :GATTTCTC CTCTGCTTAT CATGTATGCC TAACAT:GAC
 AAAAAAG:AG CCTA:TCATT GCAGCCAGTA TGATAAACT
 CA:GTCTGTG GGGCTCTTA TTGCTTAT: TCCATCATCA
 TCTGTCCTGC TTGATGTCTT TGCCTATGCA CAATCATATG
 :ACCCATCAC ATCTGTATGA AGAGC:TGGA TGACTAGGAT
 TAATATTCT: AT:::TTTAG GTTCTTATT: CAGCAGAAAT
 ATTAGATAA: TCAATGTCTT TTTATTCTG TAGGTGTGAA
 ATCCAGACAA TTGAAGATGG GGCATATCAG AGCCT:AAGC
 CACCTCTCTA CCTTAATATT GACAGGAAAC CCCATCCAGA
 GTTAGGCCCT GGGAGCCCTT TCTGGACTAT CAAGTTACA
 GAAGCTGGTG GCTGTGGAGA CAAATCTAGC ATCTCTAGAG
 AACTCCCCA TTGGACATCT CAAAACTTG AAAGAACTTA
 ATGTGGCTCA CAATCTTATC CAATCTTCA AATTACCTGA
 GTATTTTCT AATCTGACCA ATCTAGAGCA CTGGACCTT
 TCCAGCAACA AGATTCAAAG TATTTATTGC ACAGACTTGC
 GGGTTCTACA TCAAATGCC CTACTCAATC TCTCTTACA
 CCTGTCCCTG AACCCATGA ACTTTATCCA ACCAGGTGCA
 TTTAAAGAAA TTAGGCTTCA TAAGCTGACT TTAAGAAATA
 ATTTGATAG TTTAAATGTA ATGAAAACCT GTATTCAAGG
 TCTGGCTGGT TTAGAAAGTCC ATCGTTGGT TCTGGGAGAA
 TTTAGAAATG AAGGAAAACCT GGAAAAGTTT GACAAATCTG
 CTCTAGAGGG CCTGTGCAAT TTGACCATTG AAGAATTCCC
 GATTAGCATA CTTAGACTAC TACCTCGATG ATATTATTGA
 CTTATTTAAT TGGTTGACAA ATGGTTCTTC ATTTCCCTG
 GTGAGTGTGA CTATTGAAAG GGTAAAAGAC TTTCTTATA
 ATTTGGATG GCAACATTG GAATTAGTTA ACTGTAAATT
 TGGACAGTTT CCCACATTGA AACTCAAATC TCTCAAAGG
 CTTACTTTCA CTTCCAACAA AGGTGGGAAT GCTTTTCAG
 AAGTTGATCT ACCAAGCCTT GAGTTCTAG ATCTCAGTAG
 AAATGGCTTG AGTTCAAAG GTTGCTGTT TCAAAGTGAT
 TTTGGGACAA CCA:GCCT:A AAGTATTAG ATCTGAGCTT
 CAATGGTGT A:TTACCATG AGTTCAAAC TCTTGGGCTT
 AGAACAA:ACT AGAACATCTG GATTTCCAGC ATTCCAATT
 GAAACA:AAT GAGTGAGTT TCAGTATTCC TA:TCACTCA
 GAAA:CCT:C ATTTACCTTG ACATTTCTCA TACTCACACC
 AGAGTTGCTT TCAATGGCAT CTTCAATGGC TTGTCCAGTC
 TCGAAGTCTT GAAAATGGCT GGCAATTCTT TCCAGGAAAA
 CTTCCCTCCA GATATCTCA CAGAGCTGAG AAACATTGACC

FIG. 9 (Continued)

17/18

TTCCTGGACC TCTCTCAGTG TCAACTGGAG CAGTTGTCTC
CAACAGCATT TAACTCACTC TCCAGTCTTC AGGTACTAAA
TATGAGGCCAC ACAACTTCT TTTCATGGA TACGTTCCCT
TATAAGTGTG TGAACCTCCCT CCAGGTTCTT GATTACAGTC
TCAATCACAT AATGACTTCC AAAAACAGG AACTACAGCA
TTTTCCAAGT AGTCTAGCTT TCTTAAATCT TACTCAGAAT
GACTTTGCTT GTACTTGTGA ACACCAGAGT TTCCCTGCAAT
GGATCAAGGA CCAGAGGCAG CTCTGGTGG AAGTTGAACG
AATGGAATGT GCAACACCTT CAGATAAGCA GGGCATGCCT
GTGCTGAGTT TGAATATCAC CTGTCAGATG AATAAGACCA
TCATTGGTGT GTCGGTCCTC AGTGTGCTTG TAGTATCTGT
TGTAGCAGTT CTGGTCTATA AGTTCTATT TCACCTGATG
CTTCTTGCTG GCTGCATAAA GTATGGTAGA GGTGAAAACA
TCTATGATGC CTTTGTATC TACTCAAGCC AGGATGAGGA
CTGGGTAAGG AATGAGCTAG TAAAGAATT AGAAGAAGGG
GTGCCCTCCAT TTCAGCTCTG CCTTCACTAC AGAGACTTTA
TTCCCGGTGT GGCCATTGCT GCCAACATCA TCCATGAAGG
TTTCCATAAA AGCCGAAAGG TGATTGTTGT GGTGTCCCAG
CACTTCATCC AGAGCCGCTG GTGTATCTT GAATATGAGA
TTGCTCAGAC CTGGCAGTTT CTGAGCAGTC GTGCTGGTAT
CATCTTCATT GTCCTGCAGA AGGTGGAGAA GACCCTGCTC
AGGCAGCAGG TGGAGCTGTA CCGCCTTCTC AGCAGGAACA
CTTACCTGGA GTGGGAGGAC AGTGTCTGG GGCAGGACAT
CTTCTGGAGA CGACTCAGAA AAGCCCTGCT GGATGGTAAA
TCATGGAATC CAGAAGGAAC AGTGGGTACA GGATGCAATT
GGCAGGAAGC AACATCTATC TGAAGAGGAA AAATAAAAAC
CTCCTGAGGC ATTTCTTGCC CAGCTGGTC CAACACTTGT
TCAGTTAATA AGTATTAAT GCTGCCACAT GTCAGGCCTT
ATGCTAAGGG TGAGTAATT CATGGTGCAC TAGATATGCA
GGGCTGCTAA TCTCAAGGAG CTTCCAGTGC AGAGGGAATA
AATGCTAGAC TAAAATACAG AGTCTTCCAG GTGGGCATTT
CAACCAACTC AGTCAAGGAA CCCATGACAA AGAAAGTCAT
TTCAACTCTT ACCTCATCAA GTTGAATAAA GACAGAGAAA
ACAGAAAGAG ACATTGTTCT TTCCCTGAGT CTTTGAATG
GAAATTGTAT TATGTTATAG CCATCATAAA ACCATTTGG
TAGTTTGAC TGAACTGGGT GTTCACTTT TCCTTTTGA
TTGAATACAA TTTAAATTCT ACTTGATGAC TGCACTCGTC
AAGGGGCTCC TGATGCAAGA TGCCCCCTTC ATTAAAGTC
TGTCTCCTTA CAGAGGTTAA AGTCTAGTGG CTAATTCTA
AGGAAACCTG ATTAACACAT GCTCACAAACC ATCCTGGTCA
TTCTCGAGCA TGTTCTATT TTTAACTAAT CACCCCTGAT
ATATTTTTAT TTTTATATAT CCAGTTTCA TTTTTTTACG
TCTTGCTAT AAGCTAATAT CATAAATAAG GTTGTAAAG
ACGTGCTTCA AATATCCATA TTAACCACCA TTTTCAAGG
AAGTATGGAA AAGTACACTC TGTCACCTTG TCACTCGATG
TCATTCCAAA GTTATTGCCT ACTAAGTAAT GACTGTCATG
AAAGCAGCAT TGAAATAATT TGTTAAAGG GGGCACTCTT

FIG. 9 (Continued)

18/18

TTAACGGGA AGAAAATTC CGCTTCTGG TCTTATCATG
GACAATTGG GCTATAGGCA TGAAGGAAGT GGGATTACCT
CAGGAAGTCA CCTTTCTTG ATTCCAGAAA CATATGGCT
GATAAACCG GGGTGACCTC ATGAAATGAG TTGCAGCAGA
TGTATTATT TTTCAGAAC A GTGATGTT GATGGACCTA
TGAATCTATT TAGGGAGACA CAGATGGCTG GGATCCCTCC
CCTGTACCCCT TCTCACTGCC AGGAGAACTA CGTGTGAAGG
TATTCAAGGC AGGGAGTATA CATTGCTGTT TCCTGTTGGG
CAATGCTCCT TGACCACATT TTGGGAAGAG TGGATGTTAT
CATTGAGAAA ACAATGTGTC TGGAAATTAAAT GGGGTTCTTA
TAAAGAAGGT TCCCAGAAAA GAATGTTCAT TCCAGCTTCT
TCAGGAAACA GGAACATTCA AGGAAAGGA CAATCAGGAT
GTCATCAGGG AAATGAAAAT AAAAACACAA ATGAGATATC
ACCTTATACC AGGTAGATGG CTACTATAAA AAAATGAAGT
GTCATCAAGG ATATAGAGAA ATTGGAACCC TTCTTCACTG
CTGGAGGGAA TGGAAAATGG TGTAGCCGTT ATGAAAAACA
GTACGGAGGT TTCTCAAAAAA TTAAAAATAG AACTGCTATA
TGATCCAGCA ATCTCACTTC TGTATATATA CCCAAAATAA
TTGAAATCAG AATTCAGA AAATATTAC ACTCCCATGT
TCATTGTGGC ACTCTTCACA ATCACTGTT CCAAAGTTAT
GGAAACAACC CAAATTCCA TTGGAAAATA AATGGACAAA
GGAAATGTGC ATATAACGTA CAATGGGGAT ATTATTCAAGC
CTAAAAAAAG GGGGATCCT GTTATTATG ACAACATGAA
TAAACCCGGA GGCCATTATG CTATGTAAAA TGAGCAAGTA
ACAGAAAGAC AAATACTGCC TGATTTCATT TATATGAGGT
TCTAAAATAG TCAAACTCAT AGAACAGAG AATAGAACAG
TGGTTCTAG GGAAAGGAG GAAGGGAGAA ATGAGGAAAT
AGGGAGTTGT CTAATTGGTA TAAAATTATA GTATGCAAGA
TGAATTAGCT CTAAGATCA GCTGTATAGC AGAGTCGTA
TAATGAACAA TACTGTATTA TGCACCTAAC ATTTGTTAA
GAGGGTACCT CTCATGTTAA GTGTTCTTAC CATATACATA
TACACAAGGA AGCTTTGGA GGTGATGGAT ATATTTATTA
CCTTGATTGT GGTGATGGTT TGACAGGTAT GTGACTATGT
CTAAACTCAT CAAATTGTAT ACATTAAATA TATGCAGTTT
TATAATATCA AAAAAAAA AAAAAAAA

FIG. 9 (Continued)

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/15723

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C12N15/12	C12N15/63	C12N5/10	C12Q1/68	C07K14/705
	G01N33/68	A01K67/027			

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12Q C07K G01N A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, CHEM ABS Data, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>ALEXANDER POLTORAK ET AL.: "Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene" SCIENCE, vol. 282, 11 December 1998 (1998-12-11), pages 2085-2088, XP002145980 LANCASTER, PA US cited in the application abstract page 2086, right-hand column, last paragraph -page 2087, left-hand column, paragraph 2; figure 2 ----</p> <p style="text-align: center;">-/--</p>	1-3, 5, 6, 8, 9, 11-21, 23, 24, 28-30

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

19 September 2000

Date of mailing of the international search report

04/10/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patenttaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Montero Lopez, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/15723

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SALMAN T. QURESHI ET AL.: "Endotoxin-tolerant mice have mutations in Toll-like receptor (Tlr4)" THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 189, no. 4, 15 February 1999 (1999-02-15), pages 615-625, XP000900609 cited in the application page 616, left-hand column, paragraph 3 page 618, right-hand column, paragraph 2 -page 623, right-hand column, last paragraph ---	1-3, 5, 6, 8, 9, 11-21, 23, 24, 28-30
X	WO 98 50547 A (SCHERING CORPORATION) 12 November 1998 (1998-11-12) page 7, line 5 - line 35 page 8, line 26 -page 10, line 12 page 12, line 21 -page 13, line 11 page 14, line 32 -page 18, line 9 page 24, line 19 - line 30 page 29, line 23 -page 30, line 23 page 37, line 20 -page 43, line 11 page 52, line 33 -page 53, line 4 ---	1, 2, 5, 8, 11-20, 23, 28-30
P, X	N.C. ARBOUR ET AL.: "Missense mutations of the TLR4 gene are associated with hyporesponsiveness to lipopolysaccharides (LPS) in humans" AMERICAN JOURNAL OF HUMAN GENETICS, vol. 65, no. 4, October 1999 (1999-10), page A97 XP000900485 abstract no. 506 ---	1-24, 28-32
P, X	NANCY C. ARBOUR ET AL.: "TLR4 mutations are associated with endotoxin hyporesponsiveness in humans" NATURE GENETICS, vol. 25, no. 2, June 2000 (2000-06), pages 187-191, XP000900719 the whole document -----	1-24, 28-35

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 25-27

Present claims 25-27 relate to an agent defined by reference to a desirable characteristic or property, namely altering TLR4 activity. The claims cover all agents having this characteristic or property, whereas the application does not provide support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for any specific example of such agent. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the agent by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, no search has been carried out for claims 25-27.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

national Application No

PCT/US 00/15723

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9850547 A	12-11-1998	AU 7175498 A		27-11-1998